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ABSTRACT 
Neutrophil (PMN) inflammatory functions, including cell adhesion, diapedesis, and phagocyto-
sis, are dependent on the mobilization and release of various intracellular granules/vesicles. In 
this study, I found that treating PMN with damnacanthal, a Ras family GTPase inhibitor, resulted 
in a specific release of secondary granules, but not primary or tertiary granules, and caused dy-
sregulation of PMN chemotactic transmigration and cell surface protein interactions. Analysis of 
the activities of Ras members identified Ral GTPase as a key regulator during PMN activation 
and degranulation. In particular, Ral was active in freshly isolated PMN, while chemoattractant 
stimulation induced a quick deactivation of Ral that correlated with PMN degranulation. Over-
expression of a constitutively active Ral (Ral23V) in PMN inhibited chemoattractant-induced 
secondary granule release. By subcellular fractionation, I found that Ral, which was associated 
with the plasma membrane under the resting condition, was redistributed to secondary granules 
after chemoattractant stimulation. Blockage of cell endocytosis appeared to inhibit Ral transloca-
tion intracellularly. In conclusion, these results demonstrate that Ral is a critical regulator in 
PMN that specifically controls secondary granule release during PMN response to chemoattrac-
tant stimulation.    
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CHAPTER I 
GENERAL INTRODUCTION 
1. Neutrophils (PMN)  
Neutrophils, also termed PMN, are polymorphonuclear leukocytes characterized by their multi-
lobed nuclei [1]. PMN, which are generated from bone marrow, are abundant cells in circulation 
and account for 40-75% of all leukocytes [2]. Up to 1-2×10
11
 PMN are steadily generated per 
day in a healthy adult [3]. Constant numbers of PMN in the circulation are very crucial for main-
taining host homeostasis [4-6]. Granulocyte colony stimulating factor (G-CSF) has been shown 
to positively regulate PMN production in bone marrow, but G-CSF is not completely required 
for PMN generation [7-8]. The release of PMN from bone marrow is largely dependent on 
CXCR4 [9]. It is likely that CXCR4 functions a gatekeeper for blocking PMN migrating out of 
bone marrow [10-15]. In CXCR4-deficient chimera mice, myeloid precursors are significantly 
decreased and peripheral granulocytic cells are increased by about three-fold compared with wild 
type-litter mates [16-17]. Blocking CXCR4 function with the inhibitory antibody/antagonist, 
AMD3100, elevates PMN counts in circulation [10, 14-15]. Additionally, AMD3100 dose-
dependently increases the release of CD34+ hematopoietic progenitor cells into circulation as 
demonstrated in healthy human volunteers [10, 14]. Presumably, the negative effect of CXCR4 is 
through the signaling cascade of CXCL12 (stromal derived factor-1, SDF-1)/ CXCR4 [18]. Un-
der the influence of inflammation, however, PMN production is increased. In circulation, non-
activated PMN have 8-16 hours average half-lives [19]. After stimulation, active PMN are re-
cruited to the target tissue where they survive for only 1-4 days [20-21]. PMN are disposed from 
circulation mainly at the spleen, liver, bone marrow and the site of inflammation [22-24]. Ma-
crophages play a pivotal role in the clearance of both circulating PMN under nonpathologic con-
2 
ditions and inflammatory PMN in the target tissue [4]. In addition to macrophage phagocytosis, 
PMN apoptosis [21] is also a key factor in preventing excessive PMN infiltration-mediated in-
flammation, tissue damage and organ dysfunction, thus maintaining cellular homeostasis.   
 
PMN are the first cells recruited to the site of an infection [25]. Recruitment of circulating PMN 
from blood vessels to the site of inflammation is very important for eliminating invading micro-
organisms, recovering tissue damage and maintaining homeostasis [26]. Through releasing reac-
tive oxygen species, antimicrobial proteins, proteolytic enzymes and producing cytokines, as 
well as performing phagocytosis, PMN eliminate microorganisms, and thus are essential for in-
nate immunity [27]. Most notably, PMN infiltration is the hallmark of the early stages of the in-
flammatory response [28]. On the contrary, dysregulated PMN functions are also closely linked 
to tissue damage and organ dysfunction.  
 
I. Chemoattractants and their receptors in PMN transmigration 
Leukocyte chemoattractants include interleukin (IL)-4, IL-8, platelet-activating factor (PAF), and 
formyl-Methionyl-Leucyl-Phenylalanine (f-Met-Leu-Phe, fMLF), leukotriene B4 (LTB4), C3a 
and C5a [29]. Leukocyte chemoattractants can be further grouped into several main categories 
such as chemokines [30], bacterial products, immunoproducts, phospholipids, etc.  They are re-
leased by numerous types of cells.  For example, activated endothelial cells secrete IL-4, LTB4, 
and PAF, while activated stromal cells, including macrophages, epithelial cells, etc. secrete 
LTB4 and PAF. In addition, bacteria or dying cells release fMLF [31].  The combination of 
chemoattractants and their gradient drives PMN chemotactic migration towards an inflammatory 
site [31] (Figure 1-1). 
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According to derivation, chemoattractants can be further divided into “regulatory cell-derived 
chemoattractants” and “end target-derived chemoattractants”. Regulatory cell-derived chemoat-
tractants include IL-8 and LTB4, etc. End target-derived chemoattractants are mainly composed 
of fMLF, derived from bacteria or the mitochondria of dying cells, and complement C3a and C5a 
[31]. Migrating out of the blood stream, PMN encounter a combination of chemoattractants re-
leased from the endothelium and infected tissues. Through integration of those series of che-
moattractants, PMN effectively reach the target site. It has been proposed that chemoattractant 
receptor cross-desensitization is one of the mechanisms regulating PMN chemotaxis [32-34]. 
Moreover, the combinational and sequential signals of distinct chemoattractants navigate PMN 
chemotaxis to a great extent [35-37]. When placed in a chemoattractant gradient, PMN vigorous-
ly migrate towards the gradient in spite of the original migration pathways. Furthermore, PMN 
are able to integrate signals from different chemoattractants, and thus migrate toward the target. 
End target-derived chemoattractants, such as fMLF and C5a, however, are substantially domi-
nant over cell-derived chemoattractants, such as IL-8 and LTB4 [35-37].  
 
Pre-exposure with fMLF or C5a causes PMN to lose the response to IL-4 and LTB4. This phe-
nomenon might be a reasonable explanation for the fact that PMN respond to eliminate existing 
invading bacteria first compared to tissue damage. It has also been demonstrated that PMN fail to 
transmigrate towards IL-4 or IL-8 when cells are pre-treated with fMLF or C5a in the presence 
or absence of an endothelial monolayer. This desensitization of PMN is likely associated with 
the polymerization of actin filaments [36], because the end target-derived chemoattractants trig-
ger sustained and prolonged actin polymerization. Other studies have shown that PMN are able 
4 
to migrate down a concentration gradient towards another chemoattractant. They can also mi-
grate beyond the inhibitory maximum concentration toward another different chemoattractant 
[35]. In addition to the signals received by PMN upon stimulation with different chemoattrac-
tants, chemoattractant receptor cross-desensitization also plays a key role in PMN chemotaxis. 
Cpd43, an agonist of formyl peptide receptors 1 and 2, not only inhibits the ability of PMN to 
further respond to IL-8, C5a and LTB4, but also results in the loss of the expression of CXCR1, 
CXCR2, C5a and LTB4 on cell surface [33]. Treatment of PMN with fMLF or C5a reduces the 
binding of IL-8Rβ  to its antibody [34]. These miscellaneous factors enable PMN efficiently and 
precisely mobilize to their targets through a complex chemotactic field. 
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Figure 1-1. PMN activation and category of chemoattractants 
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II. Chemoattractant, fMLF-mediated signaling transduction cascade in PMN  
Various signaling pathways are implicated in PMN migration. One of the well characterized 
pathways is fMLF-mediated PMN stimulation [38] (Figure 1-2). Upon fMLF binding, its trime-
tric G-protein-coupled receptor (GPCR), composed of α, β, and γ subunits [39], is activated and 
undergoes a conformational change. Ligand binding induces the switch of GDP-bound inactive 
form to the GTP-bound active form, resulting in the low affinity of Gα towards Gβγ. The dissocia-
tion of Gα with Gβγ activates its own individual downstream effectors, including phosphatidylino-
sitol-specific phospholipase-Cβ (PLCβ), adenylyl cyclase and phosphatidylinositiol-3 kinase iso-
forms (PI3K).  
 
Activated PLCβ hydrolyzes PI 4, 5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and di-
acylglycerol (DAG). IP3 then diffuses into the cytosol, binds to the IP3 receptor and results in 
Ca
2+
 release from ER storage. Released Ca
2+
 involves in activation of PKC and triggers extracel-
lular calcium influx, presumably through the interaction of the IP3 receptor with plasma mem-
brane channels [40-42]. Ca
2+
, a pivotal second messenger, is crucial for the reorganization of ac-
tin filaments. Ca
2+
 facilitates the binding of myosin, the motor protein, to actin through exposing 
the myosin binding site on actin, and thus is involved in plasma membrane protrusion, lamella-
podia formation, and PMN migration [43]. DAG activates protein kinase C (PKC), thus resulting 
in a series of protein phosphorylation. Serving as a second messenger, PKC further activates a 
series of downstream signaling molecules involved in PMN adhesion [44-45]. In PMN, PKC al-
so associates with the respiratory burst [46]. There are five isoforms of PKC expressed in PMN, 
including PKC-α, PKC-β1, PKC-βII, PKC-δ, and PKC-δ [47]. It has been shown that, shortly 
after fMLF stimulation, PKC-α, PKC-β1, PKC-βII and PKC-δ activate NADPH oxidase, leading 
7 
to superoxide anion generation [47]. As demonstrated by in vitro phosphorylation assays, among 
the different PKC isoforms are PKC-α, PKC-βII, PKC-and PKC-δ phosphorylate p47phox and 
DADPH oxidase [48]. Inhibition of PKC-β with its specific inhibitor results in abolished activity 
of NADPH oxidase activity induced by PMA [49]. PKC-β-/- mice, however, show a defect only 
in NADPH oxidase activity, suggesting that PKC-β may not be associated with PMN migration 
[49-50].  
 
Upon dissociation with Gα, the Gβγ subunit also activates PI3K, leading to actin polymerization 
[51-53]. PMN express four types of PI3K, including PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ [54], 
which are involved in cytoskeleton organization and respiratory burst. PI3Kγ-/- PMN demon-
strate impaired migration in Casein- and Listeria–induced peritonitis mice models [55], and ab-
olished transmigration towards fMLF as illustrated in in vitro transmigration assays [50, 55]. In-
hibition of PI3Kδ by a specific inhibitor, IC8711, diminishes PMN spreading in response to 
fMLF stimulation, and also blocks PMN chemotaxis [56], implicating the important role of 
PI3Kδ in PMN directional movement. Similar effects are also observed in wortmannin or 
LY294002 (PI3K inhibitors) -treated HL-60 cells [57]. Treatment of PMN with wortmannin, re-
verses anti-β3-integrin mAb-mediated inhibited migration in response to fMLF [54], suggesting 
that the effect of PI3K in PMN migration is likely through targeting β3-integrin. PI3γ, on the 
other hand, also contributes to PMN respiratory burst through phosphorylating PIP2 into PI 3, 4, 
5-bisphosphate (PIP3), which activates PKC [53].  
 
In contrast to PLCβ and PI3K, the role of adenylyl cyclase in PMN is not well understood. Stu-
dies have shown that fMLF leads to a transient increase of cAMP in PMN through augmenting 
8 
the adenylyl cyclase response [58]. Elevated cAMP has been shown to inhibit PMN chemotaxis 
to fMLF [59]. However, limited studies exploring the role of cAMP in PMN utilizing inhibitors 
of phosphodiesterase have been performed. Blocking the breakdown pathway of cAMP using 
inhibitors of phosphodiesterase results in markedly impaired adhesion of PMN to the endothe-
lium and decreased cell surface expression of CD11b/CD18 [60], suggesting adenylyl cyclase is 
involving in the PMN adhesion step.  
 
Moreover, fMLF activates Rho small GTPase, including Rho, Rac and Cdc42, all of which regu-
late PMN migration through affecting actin filament formation [39, 52]. The MAPK cascade is 
also activated after fMLF stimulation, thus leading to chemotaxis activation and superoxide pro-
duction [38-39]. Considering the complex signaling cascades in stimulated PMN, the fMLF-
mediated signaling pathway is very critical to PMN chemotactic migration and superoxide pro-
duction.  
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Figure 1-2. fMLF-mediated activation pathway in PMN. 
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III. Key adhesion molecules involved in PMN transendothelial and transepithelial migration  
As a first line of defense, PMN are required to respond quickly to the invading microorganism. 
They transmigrate toward the sites of injury or inflammation under the influence of the chemoat-
tractant gradient. Depending on the target site, PMN transmigration toward the infectious site is 
generally composed of transendothelial migration and transepithelial migration (Figure 1-3). 
Along the process, PMN transform from resting cells into activated cells and directionally mi-
grate toward the target site. A variety of adhesive molecules, cell surface receptors, signaling 
molecules and adaptor molecules are involved in this transition.  
 
Upon chemoattractant stimulation, adhesion molecules are gradually released from secondary 
and tertiary granules of PMN to the surface. This vital degranulation process enables PMN to 
adhere and migrate across the vascular endothelium and tissue layers [26, 61-65]. β2 integrin 
CD11b/CD18, also termed as Mac-1 or αMβ2 [66-67], and Ig superfamily members, including 
CD47 and SIRPα [68-71], are all required for PMN adhesion and chemotaxis. PMN transendo-
thelial migration (Figure 1-4) is composed of tethering and rolling, adhesion and transmigration 
[26, 31, 65, 72]. Among those steps, integrin CD11b/CD18 (Figure 1-5) plays a conclusive role 
in the PMN adhesion step through interacting with its ligand, intercellular adhesion molecule 
(ICAM)-I [73] located on endothelial cells. It has been shown that CD11b/CD18, mainly loca-
lized in the secondary granules of PMN, translocate into the plasma membrane upon stimulation 
of PMN with fMLF, PMA or ionomycin [74]. The attachment of activated PMN to unstimulated 
human umbilical vein endothelial cells (HUVEC) is blocked in the presence of anti-CD11b mo-
noclonal antibodies (mAbs) [75-77]. The adherence of unstimulated PMN to stimulated HUVEC 
11 
is also inhibited by anti-CD11bAb, LM2/1 [78]. In CD11b/CD18 deficient mice, the attachment 
of PMN to ICAM-1 is decreased compared with wild-type mice [79].  
 
CD11b/CD18-mediated adhesion not only extensively contributes to transendothelial migration 
but also transepithelial migration (Figure 1-6). PMN transepithelial migration consists of adhe-
sion, migration and post-migration [67, 80-81]. Adhesion of PMN to epithelial cells is mediated 
by the interaction of CD11b/CD18 on PMN with its ligands, fucosylated proteoglycan(s), located 
on epithelial cells. This interaction triggers the opening of apical junction complex mainly 
through regulation of myosin phosphorylation. As a result, following phosphorylation, junction 
complexes open and facilitate PMN transmigration. Upon reaching the lumen, CD11b/CD18 in-
teracts with ICAM-1 on the apical epithelial site and further assists PMN transepithelial migra-
tion toward the damaged site [65]. 
 
In addition to CD11b/CD18, CD47, SIRPα and JAM-A are also actively involved the process of 
PMN transmigration. CD47 (Figure 1-7) is an important regulator in facilitating PMN transmi-
gration. In PMN, CD47 is kept in the secondary granules and is re-distributed to the cell surface 
after chemoattractant stimulation, leading to the promotion of PMN migration [69]. It was first 
discovered that PMN migration was inhibited in the presence of anti-CD47 antibodies [71, 82-
83]. Later research further demonstrated PMN transmigration across T84 monolayers and cell-
free collagen-coated filters is delayed when cell are treated with inhibitory anti-CD47 antibodies 
C5D5 and B6H12 [69]. Indeed, functionally inhibitory anti-CD47 mAbs delay, but do not block, 
the process of PMN transepithelial migration and migration across a collagen-coated transwell 
toward fMLF [69]. When challenged with Escherichia coli, CD47-/- mice demonstrated a defect 
12 
in the early stages of PMN migration [84]. In addition to its effect in PMN, CD47 has been im-
plicated in the migration in other cell types. Likewise, CD47-/-epidermal dendritic cells (DCs) 
demonstrate decreased migration toward draining lymph nodes in vivo [29]. Transduction of 
neuroblastoma cells with CD47 results in neurite and filopodium formation [85]. Additionally, 
through in vitro experimentation, it is uncovered that CD47 is important for the migratory activi-
ty of B cells [86].   
 
SIRPα (Figure 1-7), a counter ligand for CD47 [87], also contributes greatly in PMN migration. 
Similar to the distribution of CD47 in PMN, SIRPα translocates from secondary granules to the 
cell surface after fMLF stimulation [68, 70]. PMN transepithelial migration is inhibited using 
anti-SIRPα mAbs. The SIRPα-CD47 interaction leads to significantly decreased PMN migration 
[68], suggesting that SIRPα delivers a negative signal to PMN migration through its immunore-
ceptor tyrosine-based inhibition motif (ITIM).  
 
Junctional adhesion molecule-A (JAM-A) is also engaged in regulating PMN migration, particu-
larly in PMN transendothelial migration [81, 88]. JAM-A redistributes to the cell surface under 
inflammatory condition [89], thus facilitating PMN migration. Treatment of HUVECs with a 
blocking antibody against JAM-A [90] impairs PMN transmigration. The effect of JAM-A is 
likely through the interaction of JAM-A with its ligand, β2 integrin LFA-1, on leukocytes [90]. 
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Figure 1-3. PMN transmigration to the target site.  Depending on the target site, PMN transmi-
gration towards the infectious site is generally composed of transendothelial migration and tran-
sepithelial migration.  
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Figure 1-4. PMN transendothelial migration. 
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Figure 1-5. Putative structure of integrin CD11b/CD18. CD11b/CD18 is composed of α and β 
subunits.  
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Figure 1-6. PMN transepithelial migration. 
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Figure 1-7. Putative structure of SIRPα (left) and CD47 (right). 
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2. Inflammation  
Throughout evolutionary history, human beings have continued to defend against invasion by 
microorganisms. We successfully resist to infections most of time because of our complex im-
mune system. The immune system includes both the innate immunity and the adaptive immunity. 
Innate immune immunity takes place first and occurs within the first 96 hours. PMN and macro-
phages are the key players for innate immunity. Through phagocytosis, they eliminate invading 
microorganisms. Incomplete clearance results in the response of the adaptive immune system 
mainly involving in lymphocytes. Coordination of the innate immunity with the adaptive immun-
ity is crucial to fight efficiently against infection.  
 
Inflammation is an innate immune response to local injury or infection [28] (Figure 1-8). The 
occurrence of inflammation is due to insufficient removal of invading microorganism. In in-
flammation, innate immune response takes place first [91]. In the local environment, resident tis-
sue cells sense the presence of pathogens, secret cytokines acting on other cells and trigger the 
innate immune response. Under the influence of cytokine networks, vascular dilation occurs and 
edema takes place, characterized by the leaking of plasma and fluid into connective tissues due 
to the permeability change of endothelial cells. At the same time, edema leads to a change in the 
nervous system, thus resulting in a feeling of pain [28]. In addition to vascular events, cellular 
events also play a primary role in inflammation. In the local environment, high concentrations of 
chemoattractants secreted by activated stromal cells, including activated endothelia cells and ma-
crophages, etc. [31], and increased surface expression of adhesion molecules on the endothelium 
lead PMN to undergo rolling, activation, adhesion and transmigration across the endothelial mo-
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nolayer to the targeted tissue to release anti-microbial substances and phagocytize pathogens 
[92].  
 
PMN are vital for the beginning stage of inflammation [25]. PMN infiltration is the hallmark of 
the early-stage of inflammatory response [28]. After they arrive at the target site, PMN execute 
their function by releasing reactive oxygen species, antimicrobial proteins and proteolytic en-
zymes, as well as by producing cytokines and performing phagocytosis [27]. Thus, sufficient re-
cruitment of PMN is very important for eliminating invading microorganisms, recovering tissue 
damage and maintaining homeostasis [26]. In particular, during acute infection and inflamma-
tion, PMN sense chemoattractant signals and swiftly migrate across the microvasculature and 
underlying tissues to accumulate at inflammatory foci. Here, these cells execute forceful antimi-
crobial and tissue damaging functions. Therefore, the timely and precise response of PMN is crit-
ical for innate immune response. 
 
In spite of the critical role of PMN in acute inflammation, efficient removal of PMN in the late 
stage of inflammation is substantial [93-94]. PMN apoptosis [95] and removal by macrophages 
control the extent of inflammation. The prolonged existence of PMN in the targeted tissue also 
frequently results in host-tissue damage. PMN-mediated inflammation is one of the central com-
ponents of many pathophysiological processes; thus, diseases in which dysregulated PMN 
transmigration and activation occur often result in severe tissue injuries and organ dysfunction 
[25, 96]. Many active stage of human diseases are characterized by excessive PMN infiltration, 
including bacterial infection, inflammatory bowel disease, ischemia-reperfusion injury, rheuma-
toid arthritis, etc. [31].   
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Furthermore, resident tissue cells such as macrophages and dendritic cells contribute largely to 
inflammation [93-94, 97-98]. After engulfing pathogens, macrophages secrete cytokines to fur-
ther recruit other cells for assistance. After engulfing pathogens, dendritic cells migrate toward 
secondary lymphoid organs to induce adaptive immune responses. Upon dendritic cell migration 
into the secondary lymphoid organs, degraded pathogens are presented by major histocompatibil-
ity complex (MHC) on the surface and recognized by naive T lymphocytes. Activation through 
recognition of the MHC-antigen complex with T cell receptors and co-stimulatory signals causes 
pathogen-specific T lymphocytes to differentiate to T helper cells or cytotoxic T cells. T helper 
cells are able to activate B cells leading to the generation of plasma cells and secrete antibodies. 
Some plasma cells and antibodies leave lymphoid organs and enter infectious tissues for elimi-
nating pathogens. Through releasing cytokines, T helper cells also further activate macrophages 
in the tissue to increase their abilities to phagocytize pathogens. Compared with T helper cells, 
cytotoxic T cells migrate to the target tissue and directly remove pathogens through releasing 
cytotoxins or inducing apoptosis through a Fas ligand-Fas interaction. In conclusion, inflamma-
tion is a complex process whereby innate immunity coordinates with adaptive immunity to fight 
against pathogens.  
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Figure 1-8. PMN play a pivotal role in inflammation. PMN infiltration is the hallmark of the ear-
ly stage of the inflammatory response.  
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3. PMN granules  
Different from other cells types, circulating PMN only express a few cell surface proteins [62]. 
Instead, they keep most of those proteins in special membrane bound storages called granules 
[61] (Figure 1-9). According to size and morphology, PMN granules are composed of four cate-
gories, primary granules (azurophil granules), secondary granules (specific granules), tertiary 
granules (gelatinase granules) and secretory vesicles [63]. Each granule contains different protein 
components and possesses distinct functions. 
 
Primary granules, regarded as lysosomes, undergo limited degranulation in response to outside 
stimuli [99]. Primary granules are important storage for antimicrobial proteins, serine proteases 
[100-101] including elastase and cathepsin G [102], and proteinase 3 [63]. Myeloperoxidase 
(MPO) is a marker for primary granules [103]. It plays a key role in PMN phagocytic function, 
due to its strong antimicrobial activity [104], through interaction with H2O2 formed by superox-
ide anions in the respiratory burst system. During the process of phagocytosis, serine proteases, 
localized inside phagolysosome, work together with hypochloric acid, a final product generated 
in a series of reactions catalyzed by MPO, to execute antimicrobial activities. In addition to kill-
ing microorganisms in phagolysosomes, elastase are also released during PMN activation in re-
sponse to various chemoattractants stimulation [105]. Upon release, serine proteases play a very 
important role in chemokine modification that leads to an increased binding affinity towards the 
chemokine receptor. Chemokines modified by serine proteases gain increased chemotactic ac-
tivity for PMN ,and thus, are essential for PMN migration [100]. Serine proteases are also capa-
ble of cleaving intercellular adhesion molecules, ICAM-1 [106], vascular cell-adhesion molecule 
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1 (VCAM-1) [107] and epithelial (E)-cadherin [108], thus facilitating PMN transmigration 
across the endothelium and epithelial cells. As a result, certain primary granules not only func-
tion as lysosomes during PMN phagocytosis, but also contribute to the interaction between PMN 
and the extracellular matrix during PMN migration.   
 
Secondary granules are important stores of adhesion molecules, membrane receptors and other 
critical proteins, such as lactoferrin, fMLF receptors, CD47, SIRPα, and CD11b/CD18, facilitat-
ing PMN migration [63, 68-69]. Lactoferrin is a marker of secondary granules [103], and its an-
timicrobial activity comes from competing  with microorganisms for iron [109]. PMN from pa-
tients with neutrophil-specific granule deficiency [110] are defect in chemotaxis in response to 
stimuli, decreased binding capability to fMLF, decreased antibacterial activity and less activity in 
response to fMLF stimulation. Other cases of PMN secondary granule deficiency also illustrated 
decreased chemotaxis and impaired killing of microorganisms [111]. These characteristics fur-
ther suggest that secondary granules, enriched in receptors and adhesion molecules, are indis-
pensable for PMN to execute anti-infection functions.   
 
Tertiary granules serve as reservoirs of matrix-degrading enzymes [63]. The key component in 
tertiary granules is gelatinase. Gelatinase, also termed matrix metalloproteinases (MMPs), enzy-
matically digest extracellular matrix proteins during PMN transmigration. In human PMN, two 
MMPs have been identified. They are MMP-9 (92KDa) and leukolysin (MT6-MMP/MMP-25) 
(56KDa) [63, 112]. Compared with secondary granules, tertiary granules are more mobilized and 
easily exocytosed upon stimuli activation [99].  
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Figure 1-9. PMN granules types (A) and degranulation (B) in response to stimulation (e.g. 
fMLF). 
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Secretory vesicles are highly mobilized [99], and they contain membrane-associated receptors 
and are able to furnish PMN with the first batch of proteins for sensing and triggering activation 
during PMN-mediated immune responses [61]. Secretory vesicles contain the marker protein al-
bumin [113]. It has been demonstrated that albumin is originally from PMN plasma membranes, 
not from new synthesis, suggesting that albumin comes from endocytosis pathway. The quick 
interchange of albumin between the plasma membrane and secretory vesicles further implies that 
secretory vesicles are very sensitive to exocytosis. Furthermore, PMN are able to mobilize secre-
tory vesicles even in the absence of stimulation [114].   
 
The classification of granules does not only rely on the size and morphology of granules. The 
components in each granule depends on the time that those proteins are synthesized (targeting-
by-timing hypothesis) and the characteristics of each protein, i.e. whether it is able to co-exist to 
avoid degradation [99]. In addition to the presence or absence of MPO, the major difference be-
tween the secondary and primary granules lies in the fact that proteases stored in primary gra-
nules are in activated forms; proteases in secondary granules exist as latent forms and need to be 
activated after release from PMN. However, the detailed mechanisms underlying processing and 
targeting of granule proteins in PMN are unclear. It has been implied that the Golgi network is 
likely to function as a sorting apparatus in PMN [61]. Studies of serine proteases stored in prima-
ry granules have shown that glycosylation, a major function of the Golgi network, is not required 
for granule protein targeting [99]. Specifically, Cathepsin G does not require glycosylation for 
granule targeting [115]. Through site-directed mutagenesis, Cathepsin G lacking an N-linked 
glycosylation site was still shown to be transported to lysosomes. In addition to protein confor-
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mation and modification, such as glycosylation, protein-protein interaction is also crucial for cor-
rect granule targeting, particularly for lactoferrin, which is a key component for secondary gra-
nules [103]. A study on transport of newly synthesized lactoferrin demonstrated that the transport 
of lactoferrin was blocked by interfering ionic interaction at the plasma membrane and acidifica-
tion environment inside the cell [103].  
 
To date, the most sufficient experimental approach to investigate the localization of proteins of 
interest in PMN is subcellular fractionation, which has been previously demonstrated to success-
fully separate neutrophil plasma membranes from intracellular granules [70, 116]. Thus, in this 
study, a series of these experiments were performed to identify the localization of Ral in PMN.  
 
4. Mechanisms underlying granule release 
Mobilization of intracellular granules and vesicles also contributes, to an extraordinary degree, to 
PMN migration. As we know, cytoplasmic granules and vesicles of PMN are composed of not 
only antimicrobial proteins and proteolytic enzymes for eliminating foreign microorganisms but 
also a variety of cell surface receptors, functional proteins and granule matrix proteins involved 
in PMN extravasation. During degranulation, the PMN cell surface is incorporated with granule 
proteins and receptors. Subsequently, those fused proteins facilitate the activation of resting 
PMN to engage in cell-cell interactions and cell-extracellular matrix interactions in the process 
of transmigration. CD47, as an example, has been illustrated to facilitate PMN migration only 
after re-distribution from secondary granules to the cell surface upon chemoattractant stimulation 
[69]. As a result, controlled and effective degranulation of PMN is very important in inflamma-
tion and preventing overwhelming PMN-mediated tissue damage, thus maintaining homeostasis. 
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However, the molecular mechanism(s) by which PMN regulate individual intracellular granule 
release is still unclear. The signaling events elicited by chemoattractant stimulation (e.g. fMLF) 
leading to the release of each type of granule are still unclear. In other cell types, Ral, a Ras 
family small GTPase, involves in intracellular vesicle transportation, including both endocytosis 
and exocytosis [117-121]. Small GTPases are monomeric G proteins that are actively involved in 
many cellular functions [122]. They are further divided into five families based on sequence: 
Ras, Rho, Rab, Ran and Sar1/Arf [123]. According to structure, there are two interconvertible 
forms of small GTPases: GTP-bound active form and GDP-bound inactive form (Figure 1-10). 
Upon upstream activator binding, GDP is dissociated from the small GDP-bound form because 
of the conformation change, and is replaced with GTP. The GTP-bound form relays the signal 
from upstream to downstream through binding downstream effectors [122]. As a result, small 
GTPases serve as a molecular switch in signaling cascades. The interexchange of the GTP-bound 
form with the GDP-bound form is controlled by guanine nucleotide exchange factor (GEF) and 
GTPase activating protein (GAP). GEF triggers the formation of GTP-bound active form. GAP, 
increases the conversion of GTP to GDP, thus resulting in the formation of GDP-bound inactive 
form [122]. 
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Figure 1-10. Interchange of the GTP-bound form with the GDP-bound form of small GTPase. 
GEF: guanine nucleotide exchange factor; GAP: GTPase activating protein. 
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Given the importance of Ral in other cell types, in this study, the potential role of Ral in regulat-
ing PMN granule mobilization and chemotactic function was investigated. 
 
To date, the dynamics of actin cytoskeleton, Ca
2+
 signaling, src family kinases, β-arrestin, small 
GTPases and SNARE molecules have been reported to be involved in PMN degranulation.  
 
Small GTPases play important roles in regulating PMN granule release. Rac2, a Rho family 
GTPases family member, is pivotal for neutrophil primary granule release [124-127]. Rac2-/- 
mice have shown defects in PMN primary granule release but not secondary or tertiary granule 
release. Rac2-/- mice also demonstrated defects in the translocation of primary granules [124].  
Bone marrow PMN isolated from Rac2-/- mice fail to release primary and tertiary granules upon 
fMLP, LTB4, and CB-LTB4 [125] stimulation. In addition, Rac2 is also associated with supe-
roxide anion (O2–·) production [125]. In animal models and patients, the Rac mutation D57N, 
characterized by the loss of binding capability to GTP, has been [110, 127] found to prevent the 
MPO release and superoxide anions production in response to fMLF and phorbol myristate ace-
tate (PMA), but not the release of secondary granules [126]. 
 
Rab, a family protein of small GTP, have been widely studied in targeting vesicles to particular 
compartments through tethering. In PMN, Rab27a has been implicated in regulating primary 
granule release through interacting with its effector protein JFC1/Slp1 [128-129]. Rab27-/- mice 
fail to release MPO upon LPS challenge. Subcellular distribution of Rab27a by fractionation and 
immunofluorescence staining further supports the fact that Rab27 is a constituent of exocytotic 
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machinery of primary granules in PMN. Rab27b has also been demonstrated to be the key com-
ponent in regulating PMN primary granule release [130].  
 
Rap1 and Rap2 are associated with PMN secondary granules but not primary granules or cytosol, 
as demonstrated by PMN subcellular fractionation and immunostaining. Accompanied with de-
granulation, Raps translocate to the plasma membrane from secondary granules, further suggest-
ing  their roles in controlling PMN secondary granule release [131].  
 
Studies have also found that Rho family small GTPases regulate granule release. Pretreatment of 
PMN with MAPK phosphorylation inhibitors diminishes phagocytosis of C albicans and granule 
mobilization. Similarly, overexpression of the dominant-negative Rac and Cdc42 in PMN, 
through viral delivery, leads to abolished phagocytosis and granule release, implicating Rac and 
Cdc42 in regulating PMN granule release through the MAPK signaling pathway [132]. 
 
As a key component of the cytoskeleton, actin filaments not only contribute to cell motility, but 
also intracellular trafficking [133]. They are also involved in endocytosis and exocytosis [134]. 
Dynamic actin assembly and disassembly are associated with PMN primary granule release. In 
particular, actin polymerization is likely to initiate the release of primary granules. Primary gra-
nules are released from PMN treated with fMLF and cytochalasin B (CB) [135]. However, stabi-
lization of actin results in inhibition of primary granule release. Inhibition of Rac also leads to 
reduced primary granule release through jeopardizing F-actin formation. Another study has sug-
gested that the actin cytoskeleton might regulate the release of all types of granules in the PMN 
in response to stimulation [136].  With the exception of secretory vesicles, CB significantly in-
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creases fMLF-simulated secondary and tertiary granule release. Additionally, CB triggers prima-
ry granule release that is failed to be released by fMLF alone. All of the above suggest that the 
actin cytoskeleton restricts the release of granules and maintains PMN in the resting condition. In 
addition to actin filaments, microtubules have been demonstrated to be associated with PMN 
granules [137]. Granule-microtubules, including primary granule-microtubule complexes and 
secondary granule-microtubule complexes, have been isolated from PMN, suggesting the critical 
role of microtubules in regulating PMN granule release.  
 
During granule release, tethering and fusion of vesicles toward the target compartment involves a 
complex process that is not well understood. SNAREs, (soluble NSF (N-ethylmaleimide-
sensitive factor), are key proteins involving in the docking and fusing of vesicles to the target 
compartment [138-140]. In human PMN, (t-) SNARE isoform syntaxin 6 has been cloned and 
shown to be localized only in the plasma membranes of resting and activated PMN [141]. In con-
trast to syntaxin 6, SNAP-23, another isoform of (t-) SNARE, localizes in tertiary and secondary 
granules in PMN and translocates to the plasma membrane upon stimulation. Antibodies against 
SNAP-23 block secondary granule release, whereas, anti-syntaxin 6 antibodies, block primary 
and secondary granule release from PMN. The above suggest that SNAP-23 and syntaxin 6 par-
ticularly regulate secondary and primary granule release. Vesicle-associated membrane protein 
(VAMP)-7, a (v-) SNARE in PMN [142], has been detected in primary granules in PMN. Treat-
ment of PMN with antibodies against VAMP-7 dose-dependently abrogates primary granule, 
secondary granule and tertiary granule release. VAMP-2 and syntaxin 4 are associated with se-
cretion of secondary and tertiary granules from PMN [143]. VAMP-2 is identified in PMN. Ap-
plication of specific antibodies against 2-17aa in the N terminal of VAMP-2 to electropermeabi-
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lized PMN leads to the inhibition of secondary and tertiary granule release, but not primary gra-
nule release from PMN. This suggests an important role for VAMP-2 in release of those two 
granules PMN. Furthermore, VAMP-2 has also been suggested to control granule release in 
PMN after stimulation through interaction with syntaxin 4, which was demonstrated by the co-
immunoprecipitation assay. Regarding the different types of granules in PMN, distinct SNAREs 
are likely to associate with each individual granule, and thus regulate PMN granule release.  
 
Although signaling pathways regulating PMN granule release are not well understood, GPCR-
mediated signaling cascades in PMN activation have been well established. As a scaffold pro-
tein, β-arrestin has been shown to be involved in PMN granule release. Upon IL-8 binding to 
CXCR1 on PMN [144], β-arrestin binds to phosphorylated receptors and forms more β-arrestin-
Hck complexes. It has been demonstrated that β-arrestin translocates from the plasma membrane 
to secondary granules in PMN upon stimulation, suggesting its potential role in regulating PMN 
secondary granule release.  
 
The effect of Src family kinases has also been demonstrated. P59
Hck 
 was first found to be mainly 
localized on granules, in contrast to plasma membranes and cytosol, in PMN [145]. Subsequent-
ly, it is found to be localized only on primary granules in PMN and is translocated to phagosomal 
membranes in HL60 cells during phagocytosis, indicating its role in regulating fusion of primary 
granules with lysosome. P55
c-fgr
 has also been detected in human PMN and it is present in PMN 
membrane portions mainly on the plasma membrane of secondary and tertiary granules. P55
c-fgr
 
partially translocates to the plasma membrane in PMN stimulated with fMLF together with 
CB[146], suggesting its role in granule release. hck
-/-
fgr
-/-
 PMN demonstrate the diminished re-
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lease of lactoferrin in response to TNF stimulation when cells are placed in tissue culture plates 
or on collagen coated surfaces, suggesting that hck and fgr are involved in PMN adhesion-
dependent granule release [147]. 
 
Calcium signaling also plays an essential role in PMN degranulation. It has been shown that in-
creased intracellular calcium levels leads to release each type of granules in a hierarchical order 
[148]. Raised intracellular calcium is not only led by extracellular calcium influx, but also by 
other factors. It has been demonstrated that intracellular calcium in PMN is increased by ligation 
of L-selectin with its ligand, sulfatides [149], fMLF stimulation [149] and cross-linking of 
CD11b/CD18 on the PMN surface using its mAb [150]. Particularly, ligation of CD11b/CD18 
induces the activation of cytoplasmic protein tyrosine kinases, such as p58
fgr
, resulting in 
CD11b/ CD18 dependent tyrosine phosphorylation. Patients with loss of β2 integrins fail to re-
sponse to TNF-mediated tyrosine phosphorylation in PMN [151-152]. Furthermore, activation of 
CD11b/CD18 phosphorylates and activates a series of proteins. The effect of CD11b/CD18 
might be Ca
2+
 dependent [153-154].  
 
In PMN, several annexins have been identified [155]. Among them, annexin I is associated with 
secondary granules, the plasma membrane and secretory vesicles, but not primary granules. The 
effect of Annexin I  likely depends on high concentrations of Ca
2+
 [156]. Annexin II, IV and VI 
are associated with all of the granule populations. The above suggests that different isoforms of 
annexin convey distinct effects on the release of different categories of granules from PMN. 
 
 
5. Ral   
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The molecular mechanisms underlying PMN degranulation are still poorly understood. Consider-
ing the complex signal cascades involved in each type of granule release, it still remains unclear 
how PMN control the orderly release of individual granule subsets in response to different stimu-
li.  
 
Ral is a member of Ras small GTPases. Like other small GTPases, Ral activity is regulated by 
GAP and GEF. To date, six GEFs have been identified. Based on structural similarity, they are 
further divided into two subfamilies. The first family of Ral GEFs is composed of RalGDS, 
ralGDS-like (Rgl), RalGDS-like factor (Rlf), and Ral GEF-like 3 (Rgl3). They contain Ras-GTP-
binding domains, suggesting that Ral is activated through a Ras-dependent pathway. The other 
family consists of RalGPS2/RalGEF2 and RalGPS2, without a Ras-GTP-binding domain, sug-
gesting the Ras-independent pathway for Ral activation [157]. Compared to GEFs, only two 
GAPs, GAP1 and GAP2 [157], have been identified by in vitro experiments. Ral activation in-
volves complex signal cascades including both Ras-dependent [158-161] and Ras-independent 
pathways [162-163]. Studies by Rob M.F. Wolthuis demonstrate that Ral activation requires Ras 
activation [158]. Most importantly, Ral activation correlates with Ras activation. In contrast, oth-
er studies have also illustrated that the Ras-independent activation mechanism also extensively 
contributed to Ral activation [162-163]. In Rat-2 cells [162], not only does Ral activation require 
Ras activation, but is also triggered by increasing intracellular Ca
2+
 using ionomycin. Mean-
while, PLC is also required for Ral activation induced by LPA or EGF. Ca
2+
 -mediated Ral acti-
vation is observed in platelets as well. Increased intracellular calcium levels and/or increased 
calcium influx lead to Ral activation in platelets [163]. Bhattacharya M et al., using human em-
bryonic kidney 293 cells (HEK293), discovers that RalGDS dissociation from beta-arrestin and 
35 
translocation to the plasma membrane leads to Ral activation [164]. This result implies an essen-
tial function for Ral in cytoskeletal reorganization and granule release.  
 
The detailed mechanism that inactivates Ral, however, is still unknown. Thus, it is critical that 
more studies exploring this mechanism be performed. In particular, Ral deactivation is critical 
for PMN. Results from my study suggest that the loss of Ral activity results in secondary granule 
release; through secondary granule release, adhesion molecules incorporate into the PMN sur-
face, and thus facilitate PMN migration, interaction with extracellular matrix and communication 
with other cells in inflammation.  
 
There are two Ral genes in mammalian cells. The Genebank IDs for RalA and RalB of Homo 
sapiens are AF493910.1 and X15015.1, respectively. RalA and RalB are highly homologous, 
with about 85% identical amino acids [165] (Figure 1-12). The distinct sequences are mainly lo-
cated at the carboxyl-terminus, in amino acids 192-204 [166]. RalA and RalB contain the same 
amino acid sequences within two effector binding regions, shown in Figure 1-12, suggesting that 
they are likely to harbor overlaid functions. As a typical family member of Ras small GTPase, in 
the C-terminus, Ral contains an atypical CAAX motif (where C stands for cystein, A stands for 
aliphatic amino acid, X stands for methionine or serine); CAAX is a lipid modification motif 
[167] and suggests that Ral is likely to be associated with the membrane.  
 
As shown in Figure 1-11, Ral contains two effector binding regions that are also termed “switch 
regions”, which mediate the recognition of effectors.  Ral performs distinct and important bio-
logical functions through interacting with different downstream binding partner proteins. Five 
36 
binding partners have been identified to date. They include RalBP1, Sec5/Exo84 (subunit of ex-
ocyst), PLC-δ1, and ZONAB, and phospholipase D 1 (PLD1) [168]. Except for PLD1 binding to 
the first 11 amino acids of Ral, others all bind to the switch regions. Through interaction with 
diverse effectors, Ral executes different biological functions. Particularly, Ral employs primary 
functions in vesicle trafficking through downstream effectors, RalBP1, Sec5/Exo84 and PLD1.  
 
Although Ral engages in many aspects of cellular processes, it executes its major function in ex-
ocytosis and endocytosis, mainly by regulating exocyst, which is seen in a variety cell types 
[169]. Exocyst is a protein complex composed of Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo70 
and Exo84 subunits, and is implicated in the fusion of vesicles to the plasma membrane [170]. 
The regulation of the exocyst is largely dependent on small GTPases. Ral small GTPases are key 
players in this process. A number of publications have demonstrated that Ral promotes exocyst 
assembly [171-172]. Using the double-mutant protein Ral23V49N as a probe in the yeast two-
hybrid system, active Ral was found to directly associate with Sec5, a subunit of exocyst and the 
association was confirmed by the decreased formation of exocyst in the absence of Ral [173].  
 
The functions of RalA and RalB are not completely understood. They play a collaborative role in 
regulating cytokinesis through exocyst [174], suggesting that RalA and RalB have compensatory 
roles in exocytosis. It has been postulated that dense granule releases from permeabilized plate-
lets stimulated with GppNHp, a non-hydrolyzable analog of GTP are triggered by active Ra-
lA/RalB [175].  The release of dense granules is abrogated by overexpression of Sec5- GTP-Ral-
binding domain (RBD), which suggests the secretion of dense granules from platelets is regu-
lated by the Ral-Exocyst pathway.  
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The influence of Ral on vesicle release has also been demonstrated in the neuron signaling sys-
tem. The expression of a dominant-inhibitory mutant of Ral results in dramatically inhibited re-
lease of vesicles in the presynaptic nerve terminal in response to Ca
2+
. The regulation is likely 
through active Ral-exocyst interaction [118]. In addition, active RalA interacts with the mamma-
lian brain exocyst complex [119]. In neuronal cells, chromaffin and PC12 cells, Ral associates 
with the plasma membrane in resting cells; however, after stimulation, it is thought to interact 
with effector protein(s) and form a complex. Activation of Ral in stimulated PC12 cells by K
+
 
triggers the release of large, dense core secretory granules. Furthermore, overexpression of a 
constitutively active form of Ral increases the exocytosis of those granules from PC12 cells 
[117]. 
 
In polarized epithelial cells, Ral directs vesicle transportation. Protein transportation that was 
originally directed only towards the basolateral membrane was changed to the basolateral and 
apical membranes in the presence of active Ral [173]. Overexpression of the constitutively active 
form of Ral, Ral23V, or the inhibitory construct containing the Ral-binding domain leads to the 
inhibition of granule exocytosis in PC12 cells [173].  RalB is required for exocyst complex for-
mation in rat kidney epithelial cells [176]. Active RalA binds exocyst and increases the translo-
cation of E-cadherin in epithelial cells [177]. Adhesion-mediated RalA activation is also required 
for integrin-mediated membrane raft endocytosis and recycling during regulation of growth sig-
naling [120].  
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In addition to exocytosis, it is reasonable to predict that Ral is also associated with endocytosis, 
based on studies demonstrating the function of RalBP1. RalBP1/RLIP76, another important 
downstream effector of Ral, is a member of the machinery regulating receptor-mediated endocy-
tosis [121, 178-179]. Using a two-hybrid assay, RalBP1 is found to associate with µ2, the me-
dium chain of AP2 adaptor protein complex [121] that is requisite for clathrin-mediated endocy-
tosis by recruiting clathrin to plasma membrane [180]. Overexpression of constituently active 
Ral also blocked endocytosis of transferrin in HeLa cells [121], A431 cells [178], and CHO-IR 
cells [178].  
 
Not only does Ral play a crucial role in regulating vesicle trafficking, its functions have also 
been explored in tumorigenicity [181]. In human bladder cancer [181], RalA mRNA is signifi-
cantly upregulated and is associated with invasive tumors. The RalA mRNA level is also highly 
associated with cancer protein expression [181]. RalA is required for the growth of human pan-
creatic carcinoma cells [182]. Also, inhibition of RalB by siRNA resulted in remarkably de-
creased cell migration in bladder carcinoma and prostate carcinoma cells [183]. RalB is involved 
in host defense signaling through suppressing tumor apoptosis, thus leading to cancer cell sur-
vival [184-185]. It has been shown that RalB activation promotes the complex formed between 
Sec5 and the exocyst subunit, along with TBK1 (Tank binding kinase 1), an atypical IκB kinase 
member, resulting in cancer survival.     
 
The effect of Ral in vesicle trafficking has also been elucidated through investigating the func-
tion of PLD. PLD1 and its product PA are actively involved in vesicle trafficking, exocytosis and 
endocytosis [186-187]. The role of PLD1 is likely to be regulated by ARF6, a small GTPase, due 
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to the fact that 1) the activity of PLD1 depends on ARF6, and 2) the inhibition of PLD1 activity 
by myr-Arf6 (N-terminal-myristoylated Arf6) [188] peptide leads to impaired exocytosis induced 
by calcium in chromaffin cells [189]. PLD1 functions coupled with active Ral are required for 
exocytosis. Furthermore, Ral, PLD1 and ARF6 physically associate with each other and form a 
complex, mediating exocytosis upon stimulation. The expression of a vector bearing the coding 
sequence for active Ral, but lacking in binding sequence for PLD1, fails to elicit granule release, 
indicating that Ral functions in concert with PLD1 to modulate exocytosis [117].  
 
The effect of RalA and RalB in PMN is still inconclusive. Using RT-PCR (Figure 3-19), in this 
study it was demonstrated that RalA and RalB are both present in human PMN, and RalB is 
more dominant than RalA. In my experimental approaches, I utilized a Ral pull-down assay to 
investigate the activity switch of Ral. Pull-down assays are widely accepted and used to address 
the activity of a variety of small GTPases including Ras, Rac1, Cdc42, Rho, Rap, Arf and Ral. 
The assay takes advantage of the specific interaction between RalBP1 and active Ral. It has been 
illustrated that amino acids 375-626 of RalBP1 comprise the putative binding domain that me-
diates the interaction with amino acids 37-56 of RalA [190]. As shown in Figure 1-11 and Figure 
1-12, RalA and RalB bear identical amino acid sequences in the binding domain of RalBP1. Al-
though, the Ral pull-down assay was designed originally for the detection of RalA activity, it is 
expected that RalBP1 will be able to pull-down the active form of RalB, which has been illu-
strated in another study [183]. 
 
Taken together, the current research is not focused on differentiating the role of RalA and RalB 
in regulating secondary granule release in PMN. As shown in Figure 1-11 and Figure 1-12, RalA 
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and RalB are highly homologous proteins and share most (if not all) of the functional domains 
identified to date. The possible Ral downstream effector proteins relevant to our study involving 
in receptor endocytosis, such as RalBP1/RLIP76 [121, 178-179], were found to bind to RalA and 
RalB at sites with an identical amino acid sequence (aa 37-56).  Given the overlapping functions 
of RalA and RalB, and the fact that both of these forms are expressed in PMN, we decided to use 
Ral in my study.  
 
In this dissertation, Ral, another family member of small GTPases, is demonstrated to play a vital 
role for PMN secondary granule release.   
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Figure 1-11.  Ral domain structure. The Ral domain structure was adopted from VanDam and 
Robinson [168] with modifications using NCBI’s conserved domains software.  
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82.1% identity in 206 residues overlap; Score: 855.0; Gap frequency: 1.0% 
 
RalA,          1 MAANKPKGQNSLALHKVIMVGSGGVGKSALTLQFMYDEFVEDYEPTKADSYRKKVVLDGE 
RalB,          1 MAANKSKGQSSLALHKVIMVGSGGVGKSALTLQFMYDEFVEDYEPTKADSYRKKVVLDGE 
           ***** *** ************************************************** 
 
RalA,         61 EVQIDILDTAGQEDYAAIRDNYFRSGEGFLCVFSITEMESFAATADFREQILRVK-EDEN 
RalB,         61 EVQIDILDTAGQEDYAAIRDNYFRSGEGFLLVFSITEHESFTATAEFREQILRVKAEEDK 
           ****************************** ****** *** ***+ ********* *++  
 
RalA,        120 VPFLLVGNKSDLEDKRQVSVEEAKNRAEQWNVNYVETSAKTRANVDKVFFDLMREIRARK 
RalB,        121 IPLLVVGNKSDLEERRQVPVEEARSKAEEWGVQYVETSAKTRANVDKVFFDLMREIRTKK 
           + *+*+ ********+ +***+ ****++ +** * *+ ************************ +* 
 
RalA,        180 MEDSKEKNGKKKRKSLAKRIRERCCIL 
RalB,        181 MSENKDKNGKKSSKN-KKSFKERCCLL 
           * + +*+ *****  *+  * + + ****+* 
 
Figure 1-12. Sequence alignment of RalA and RalB. Protein sequence alignment and domain 
structures of human RalA and RalB. Alignment of the primary structures of RalA and RalB re-
veals a high similarity between these proteins. The identical amino acids are indicated by “*” and 
the homologous amino acids are indicated by “+”. The different amino acids are highlighted in 
purple.   
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Summary 
This dissertation describes the regulatory function of Ral, a small GTPase, in vesicle trafficking 
in the aspect of exocytosis. In particular, my dissertation work investigates the Ral-mediated 
complex signaling pathway in the regulation of granule release from a very unique cell type, 
PMN. My work, for the first time, reports the novel finding that Ral controls secondary granule 
release from PMN (Figure 1-13). Active Ral prevents degranulation of secondary granules from 
PMN. The function of Ral as a gate-keeper for secondary granules is further illustrated by over-
expression of a constitutively active Ral during PMN chemoattractant stimulation. Inhibition of 
Ral activity is intimately related with PMN dysfunction. Thus, my work suggests that Ral is vital 
for PMN secondary granule mobilization and is intimately linked to chemotactic function. Re-
garding the pivotal role of PMN in innate immune response and inflammation, my work will 
shed new light on drug design through targeting Ral in PMN in order to defend against a variety 
of inflammatory conditions.  
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
Figure 1-13. Control of secondary granule release in neutrophils by Ral  
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CHAPTER II: 
MATERIAL AND METHODS 
2.1 PMN isolation  
2.1.1 PMN isolation by dextran-ficoll (DEAE-Ficoll) 
Human whole blood was drawn from volunteers followed by centrifugation at 200×g for 10 min 
and stopped, without breaking, to separate the platelet-rich plasma and blood cells. After decant-
ing plasma, 2% dissolved in 0.9% NaCl was utilized to separate red blood cells (RBC) from leu-
kocytes (35min, 4 °C). The upper layer containing leukocytes were collected into a new tube fol-
lowed by centrifugation (10min, 4 °C). The 10ml respuspended pellet in 0.9% NaCl was placed 
onto 3ml ficoll followed by centrifugation (40min, 4 °C). Pellet on the bottom of the tube was 
composed of PMN and RBCs, while peripheral blood mononuclear cells (PBMCs) including 
lymphocytes, monocytes and macrophages formed a layer approximately 1ml above the pellet. 
After discarding the top solution and the PBMC layer, the pellet containing PMN and RBCs was 
resuspended in cold RBC lysis buffer composed of 155 mM NH4Cl, 2 mM NaHCO3 and 0.1 mM 
EDTA. After centrifugation, PMN were resuspended in cold HBSS (-) after washing once. PMN 
were used within 4 hours of isolation. The purity of PMN isolated using DEAE-Ficoll method 
was greater than 95%. 
 
2.1.2  PMN isolation from “buffy coat” 
Human whole blood was centrifuged at 1300 rpm for 10 min at 4 °C. After removing the plasma 
and top “buffy coat”, a thin layer containing PMN was collected and kept in a new conical tube. 
In order to maximally retract PMN from the buffy coat, a thin layer of RBCs underneath the 
PMN were also collected and transferred to the same tube. To remove RBCs, two rounds of lysis 
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using hypotonic buffer containing 155 mM NH4Cl, 2 mM NaHCO3, 0.1 mM EDTA were ap-
plied. After centrifugation, PMN were resuspended in cold HBSS (-) after washing once. The 
purity of PMN isolated using this method was about 70% to 80%. 
 
2.1.3. PMN isolation using lympholyte-poly 
Human whole blood drawn from healthy donors was added on top of an equal volume of lym-
pholyte-poly (Cedarlane Laboratories Limited) in a 15ml centrifuge tube followed by centrifuga-
tion at 500g for 40 min at 25°C. After centrifugation, the RBCs were in the pellet on the bottom 
of the tube, while two visible leukocyte bands were formed at 1/3 the length of the tube. The 
PBMCs remained at the sample/medium interface (upper band) and the PMN formed a band 
(lower band). After removing the upper band containing PBMCs, PMN in the lower band were 
harvested into a new conical tube. PMN were washed twice with HBSS (-) without Ca
2+
 and 
Mg
2+
 followed by centrifugation at 400g for 10 min at 25°C. The PMN pellet was then lysed 
once with lysis buffer (Roche, Inc) to remove excessive RBCs followed by centrifugation at 
400g for 10 min at 25°C. After centrifugation, PMN were resuspended in cold HBSS (-) after 
washing once 
 
2.2 Platelet isolation 
Human whole blood was centrifuged at 1000 rpm for 10 min at 4 °C, without breaking, to sepa-
rate the platelet-rich plasma and blood cells.  The top layer containing the platelet-rich plasma 
was placed into a new tube. To isolate platelets and prevent activation during the isolation 
process, the collected plasma was supplemented with 0.1 volume ACD (2.5% trisodium citrate, 
1.5% citric acid, 2% D-glucose) followed by centrifugation at 3000rpm for 15 min. The pelleted 
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platelets were washed with a citrate buffer (120mM NaCl, 4.26mM NaH2PO4, 5.5mM glucose, 
4.77mM sodium citrate and 2.35mM citritic acid, pH 6.5), and finally resuspended in HBSS (-) 
at 4 °C. 
 
2.3 Treatment of PMN with inhibitors and agents  
For treating PMN, damnacanthal (Calbiochem) was freshly dissolved in DMSO, followed by fur-
ther dilution in HBSS(-) at concentrations ranging from 0.1µM to 18µM before incubation with 
PMN (5×10
6
 cells) at 25ºC for 15 min. Other inhibitors, such as Bruton tyrosine kinase inhibitor 
LMF-A13, Src family inhibitors PP1 and genistein, Syk inhibitor piceatannol, mitogen-activated 
protein kinase (MAPK) inhibitor SB203580 and MEK inhibitor PD98059 (all from Biomol), PI3 
kinases inhibitor LY294002 (both from Calbiochem) and others, were used as described pre-
viously [191-192]. To block the clathrin-mediated endocytosis, dynamin inhibitor dynasore [193] 
and an AP-2 binding peptide fragment of the EGFR protein tyrosine kinase substrate #15 
(Eps15-DIII) [194-195] were used as previously described. Eps15-DIII was delivered into PMN 
by tagging with HIV Tat. PMN were pre-treated with these reagents for 5-15 minutes before sti-
mulation with 1µM fMLF at 37°C. 
 
The endocytosis inhibitors phenylarsine oxide (POA) and chlorpromazine hydrochloride (CPZ) 
[196] were purchased from Sigma and freshly prepared prior to the study. POA was dissolved in 
DMSO followed by dissolving in HBSS (+) at the final concentration of 20µM, followed by in-
cubation with PMN (1.5x 10
7
) at 37ºC for 5 min before fMLP stimulation. DMSO, at a final 
concentration of 0.06%, was used as the vehicle control for POA. CPZ, sucrose (Thermo Fisher 
Scientific, Inc), NaCl (Thermo Fisher Scientific, Inc), and succinic acid pH 5.5 (Thermo Fisher 
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Scientific, Inc) [197-198] were dissolved in HBSS (+) at a final concentration of 50µM,  
500mM, 760mM and 20mM, respectively, followed by incubation with PMN (1.5x 10
7
) at 37ºC 
for 5 min. 
 
2.4 PMN degranulation assays 
To test the effect of inhibitors on resting PMN, PMN (5×10
6
) were incubated in 400µl of HBSS 
(-) with different inhibitors or the same dilution of DMSO at 25ºC for 15 min followed by centri-
fugation. Clear supernatants without cell debris were collected and assayed for specific granular 
markers including myeloperoxidase (MPO), lactoferrin and gelatinase correlating to the release 
of primary, secondary and tertiary granules, respectively [69, 191]. MPO activity was assayed 
using 2, 2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid (ABTS). Lactoferrin was assayed by 
ELISA using anti-lactoferrin antibody (Jackson ImmunoResearch Laboratories). Gelatinase was 
assayed by zymogram using gelatin-embedded gels (BioRad).  
 
To assay degranulation after chemoattractant stimulation, PMN, untreated or treated with Tat-
tagged peptides, PMN (2.5 x 10
6
) were incubated with purified Tat-tagged wild-type Ral (Ral), 
the constitutive active form (RalG23V) and dominant negative form (RalS28N) of RalA at con-
centrations of 10nM and 40nM for 15 min at 15°C followed by stimulation in 250µl HBSS (+) 
with fMLP (1µM) for 20 min at 37ºC. Following a similar procedure, supernatants without cell 
debris were collected and assayed for the release of granular markers. To assay PMN degranula-
tion after treatment with endocytosis inhibitors, PMN (1.5 x10
7
) were incubated in 1.2ml HBSS 
(+) with different inhibitors at 37ºC for 5 min followed by fMLP (1µM) stimulation at 37ºC for 
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10 min followed by assaying for the release of granular markers. Positive degranulation controls 
were performed by stimulating the same amount of PMN with fMLF plus 10µM CB [135]. 
 
2.5 PMN transmigration assay 
PMN migration across collagen-coated transfilters was performed as described previously [69, 
191]. Briefly, freshly isolated PMN (1 × 10
6
), non-treated or treated with inhibitors (15 min, 
25
o
C) or Tat-tagged Ral peptides (30 min, 4
o
C) at final concentration of 10nM and 40nM were 
loaded into the upper chambers of the transmigration setups in 150μl HBSS (+). Transmigration 
was initiated by adding 0.1μM fMLF in the lower chambers containing 500μl HBSS (+) and in-
cubation at 37°C. PMN that migrated into the lower chambers were quantified by measuring the 
activity of myeloperoxidase (MPO), a marker for primary granules. MPO was released by lysing 
plasma membrane using Triton X-100.  25μl 10% Triton X-100 was added to the lower chamber 
containing migrated PMN at a final concentration of 5%. 25μl 1M citrate buffer pH 4.2 was also 
added to the lower chamber to adjust the pH to 4.2.  Equal amounts of sample were mixed with 
the solution containing 1 mM ABTS, 10 mM H2O2, and 100 mM citrate buffer pH 4.2. Color 
matrix was developed at 405nM on a plate reader. In order to quantify the number of the mi-
grated cells in the lower chamber, a standard curve was also generated using known concentra-
tions of PMN.  
 
2.6 Ras family GTPase activation assay 
Ras GTPases activation assay in PMN 
The GTPase activities of Ras, Rap and Ral in PMN were assayed using Ras, Rap and Ral activa-
tion assay kits (Millipore) with modifications. Briefly, PMN (2×10
7
 cells/per condition) or plate-
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lets (3×10
8
 cells/per condition), with or without different treatment, were lysed with a buffer con-
taining 25mM Hepes, pH7.5, 150mM NaCl, 2mM MgCl2, 1% NP-40, 0.5% Na deoxycholate, 
1% Triton X-100, 2% glycerol and protease inhibitors (cocktail (Sigma) and 10mM PMSF) fol-
lowed by incubation with Raf-1 RBD, RalGDS-RBD or RalBP1 (residues 397-519 of rat 
RalBP1)-conjugated agarose for 45 min at 4°C. After washing the agarose, the pulled-down ac-
tive Ras, Rap and Ral were detected by Western blot. Positive and negative controls were per-
formed by addition of GTPγS or GDPγS to the cell lysates before pull-down. In addition, whole 
lysates from both control and treated cells were saved and run in parallel, serving as an internal 
loading control to determine the total amount of Ras, Rap and Ral proteins. 
 
Alternatively, active Ral in PMN was also pulled down using a RalBP1 of human origin (amino 
acids 397-518 of human RalBP1) and GST fusion protein, a gift from Dr. Johannes Bos (Utrecht 
University, Netherlands) [163]. Our results indicated that RalBP1 of either human or rat origin 
worked equally well to pull down active human Ral.  
 
Ral GTPases activation assay in platelets 
Fresh isolated human platelets (3 × 10
8
 cells/per condition) with or without thrombin stimulation 
were subjected to the Ral activation assay. Isolated platelets were stimulated with human recom-
binant thrombin (Sigma, Saint Louis) at a final concentration of 0.1UN/ml in tissue culture-
treated 6-well plates (Costar, Corning Incorporated) at 37°C for 20 min. Cells were lysed in the 
buffer containing 25mM Hepes, pH 7.5, 150mM NaCl, 1% NP-40, 1% Triton, 2% glycerol, 
0.5% Na-deoxycholate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF. After centri-
fugation, the cleared supernatant was incubated with 30 µg GST-RalBP1 (human sequence) fu-
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sion protein-coupled glutathione-sepharose with gentle agitation for 1 hour at 4°C to pull down 
the active form of Ral. The sepharose mixture was pelleted down, washed with lysis buffer. Ac-
tive Ral was detected by western blot using an anti-Ral antibody. In addition, whole cell lysates 
from unstimulated and stimulated platelets were saved and applied to western blots to assay the 
total Ral proteins.  
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Figure 2-1.  GTPase pull down assay 
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2.7 Generation of HIV Tat-tagged recombinant proteins 
A GST gene fusion system was used to express and purify Ral and Eps 15-DIII fusion proteins in 
Eschericia coli. Three pGEX-5X1 vectors expressing the full length (wild-type), the constitutive 
active form (G23V) and dominant negative form (S28N) of Ral protein were constructed (Figure 
2-2).  For Eps15, two constructs expressing Eps15-DIII with the binding ability to AP-2 and 
Eps15-Δ without the binding ability to AP-2 were obtained.  
 
2.7.1 Generation of HIV Tat-tagged Ral recombinant proteins under soluble conditions 
Briefly, to generate Tat-tagged Ral proteins, the entire cDNA of wild-type Ral was RT-PCR am-
plified from leukocytes (Marathon Ready cDNAs, Clontech) using a sense primer, 5’- atatg-
gatcccctacggccgcaagaaacgccgccagcgccgccgcatggctgcaaataagcccaagggt, (underlined) coding for 
the 11 residues of HIV Tat (YGRKKRRQRRR) [199-201], and an antisense primer, 5’-
atatctcgagttataaaatgcagcatctttc, followed by cloning into pGEX-5X1 vector through BamHI and 
XhoI site, respectively. To produce the constitutively active (Ral23V) and dominant-negative 
(Ral28N) mutants [117, 167, 202], Gly23 and Ser28 in wild-type Tat-Ral were mutated to Val 
and Asn, respectively, using GeneTailor™ Site-Directed Mutagenesis kit (Invitrogen, USA). Af-
ter production of the recombinant proteins, GST within the fusion was removed by Factor Xa 
(New England Biolabs) and the obtained Tat-tagged Ral and Eps15 proteins were obtained fol-
lowed by filtering through 0.22μm filters. To label peptides with fluorescein (FITC), an EZ-
Label FITC protein labeling kit (PIERCE) was used. For transduction into PMN, Tat-tagged pro-
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teins (10-100nM) were directly incubated with freshly isolated PMN in HBSS (-) for 10-30 min 
at 4°C.  
 
Considering the high possibility of protein precipitation due to the positive charge of HIV-Tat, 
the HIV-Tat-tagged protein is commonly purified under denatured conditions. Given that PMN 
are very prone to be activated, the common procedure for protein expression and purification of 
HIV-Tat-tagged protein was modified in this research.  
 
2.7.1.1 Induction and purification of GST-Tat-Ral fusion protein 
Followed by transformation to E. coli BL21 cells, GST fusion protein expression was induced by 
IPTG (isopropyl-beta-D-thiogalactopyranoside). In order to obtain high level of protein expres-
sion and prevent protein formation into inclusion body, the induction environment was modified 
before large-scale protein induction. Bacteria growth to the saturate status was required, and 
OD600 was measured to be 0.8 before IPTG induction.  
 
Wild-type Ral protein was induced by IPTG at a final concentration of 0.5mM at 20°C with con-
stant shaking overnight. While, the final concentration of IPTG for inducing mutant forms of Ral 
was decreased to 0.1mM due to the fact that under the same induction condition, protein expres-
sion levels of the constitutively active form (G23V) and dominant negative form (S28N) of Ral 
were very low compared with that of wild-type protein. In order to increase protein expression 
level, the final concentration of IPTG was decreased to 0.1mM to prevent protein aggregation in 
the inclusion body. 
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After IPTG induction and centrifugation, cell pellet was resuspended in 1× ice cold PBS, fol-
lowed by sonication. A clear cell lysate was obtained after centrifugation at 15000rpm for 10 min 
at 4°C. GST fusion proteins were purified by affinity purification using glutathione-sepharose 4B 
(Amersham Biosciences). Glutathione-sepharose was incubated with the clear lysate with gentle 
agitation for 2 hours at 4°C. According to the binding capacity that 1 ml drained glutathione-
sepharose is able to bind 8 mg fusion protein, a sufficient amount of glutathione-sepharose was 
added to the lysate. Medium mixed with cell lysate and sepharose was then packed into column 
(Pierce) followed by washing with 500 ml 1× ice cold PBS and eluted with10mM reduced gluta-
thione in 50mM Tris pH 8. The eluted protein was then concentrated using Millipore Amicon 
Ultra-4 10,000 mwco to the final concentration of approximately 0.6 mg/ml, followed by dialysis 
against 1×PBS by using dialysis tubing (Spectrum Spectra, 12-14,000 mwco). In order to prevent 
activation of the protein precipitation cascade, protein concentration was modified below 1 
mg/ml, and several rounds of high speed centrifugation were required to remove any small pre-
cipitants before dialysis. After dialysis and sterilization through 0.2µm filter, protein purity was 
analyzed by coomassie blue staining and western blot. 
 
2.7.1.2 Cleavage of GST-Tat-Ral fusion protein 
In order to obtain Tat-Ral proteins, GST-tag was cleaved from GST fusion protein by Factor Xa 
(NEB). Briefly, GST fusion proteins were incubated with Factor Xa at 0.3µg Factor Xa to 25 µg 
GST fusion protein at 25°C for 2.5 hours followed by incubation with glutathione-agarose with 
agitation at 4°C for 4 hours. The Tat-Ral protein in the run-through was obtained after passing 
protein mixture through the column (Pierce). Purity was then analyzed by coomassie blue stain-
ing. In particular, before cleavage, GST fusion protein concentration was adjusted below 1mg/ml 
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to prevent Tat-Ral protein precipitation during cleavage, likely due to the exposure of highly 
charged amino acids.  
 
2.7.2 Generation of HIV Tat-tagged Eps15 recombinant proteins under soluble conditions 
The same approach of generation and purification of HIV Tat-tagged Eps 15 protein as HIV Tat-
tagged Ral protein was applied. Two Tat-tagged Eps15 C-terminal peptides were produced, the 
AP-2 -binding peptide (amino acids 563-885, designated as Eps15-DIII) and non-binding peptide 
(amino acids 740-885, designated as Eps15-Δ) [194-195]. To construct these proteins, RT-PCR 
were performed using an antisense primer, 5’-tagccagttctaagtcttc, and Tat sequence-containing 
sense primers, 5’-atatggatcccctacggccgcaagaaacgccgccagcgccgccgccctgaactactgccttctggtgtga  
and 5’-atatggatcccctacggccgcaagaaacgccgccagcgccgccgctcagccacatcgagctctgtcagcaac, respec-
tively. HIV Tat-tagged Eps15 protein was expressed and purified in the same way describe in 
2.7.1.  
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Figure 2-2.  HIV-Tat-Ral expression and purification system. A) pGEX-5X1-Tat-Ral expression 
vector.  B) Structure of GST-Tat-Ral protein. There were three pGEX-5X1 vectors expressing 
the full length (wild-type), the constitutive active form (G23V) and dominant negative form 
(S28N) of Ral protein. After Factor Xa cleavage, GST-tag was removed from Tat-Ral peptide. 
C) Detailed Tat-Ral protein expression and purification workflow 
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2.8 Zymogram assay 
Gelatinase activity was assayed by gelatin zymography (Bio-Rad, Inc). Briefly, the clear super-
natant was mixed with non-reducing SDS gel sample buffer and subjected to a gelatin gel with 
10 μg protein per lane. The gel was then washed twice in 2.5% TritonX-100 in 50 mM Tris pH 
7.4, 5 mM CaCl2, 1 microM ZnCl2 at 25°C followed by incubation in the same buffer without 
Triton X-100 at 37°C for 20 h. The polyacrylamide gel was then stained with coomassie blue R-
250 for 1 hour at 25°C  followed by destaining for 30 min at 25°C . Gelatinase activity was 
shown by the white areas of loss of coomassie blue staining.  
 
2.9 Subcellular fractionation of PMN 
Freshly isolated PMN (10
8
/per condition), with or without fMLF stimulation or inhibitor treat-
ment, were lysed in a buffer containing 25mM Hepes pH7.5, 150mM NaCl, 10% sucrose, 2mM 
MgCl2 and protease inhibitors using a dounce homogenizer followed by centrifugation at 200×g 
for 5min. Meanwhile, discontinuous sucrose density gradients were prepared by layering 5 layers 
of successive decreasing sucrose density solutions (5ml/layer) upon one another (60%, 50%, 
40%, 30% and 20%). PMN lysates (10ml) were then layered on top of the gradients. After centri-
fugation with a Beckman SW28 swinging bucket ultracentrifuge rotor for 3h at 28, 000rpm 
(141,000×g) (4°C), the gradients were fractionated (1ml/fraction) followed by analysis for plas-
ma membrane (alkaline phosphatase), primary granule (myeloperoxidase), secondary granule 
(lactoferrin) and tertiary granule (gelatinase) [69-70]. 
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2.10 FITC Protein Labeling  
Tat-tagged Ral protein was fluorescently labeled using EZ-Label™ FITC Protein Labeling Kit 
(PIERCE). Briefly, Tat-tagged Ral proteins were dialyzed against BupH Borate buffer contain-
ing 50 mM borate, pH 8, using Slide-A-Lyzer MINI Dialysis Unite with 3500 MWCO (PIERCE) 
for 1 hour at room temperature to exchange protein buffer for optimizing protein labeling. After 
buffer exchange, FITC was added into protein according to the formula* and incubated at room 
temperature for 1 hour. FITC-protein mixture was then dialyzed against 1×PBS at 25°C for 1 
hour in the same dialysis unit to remove excess fluorescent dye followed by transduction to 
PMN.  
 
 
 
 
Simplified formula*:  
 
 
 
2.11.  Immunofluorescence labeling and flow cytometry   
Fresh isolated PMN (5 × 10
6
) were pretreated with tyrosine kianses and other pharmacological 
inhibitors in HBSS (-) for 10 min (20°C). After centrifugation at 1300rpm for 5 min at 4°C, the 
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cell pellet was resuspended with blocking buffer containing 0.5% BSA. Cell surface expression 
of CD11b, CD47 and SIRPα was assessed by labeling non-permeabilized PMN with anti-CD11b 
mAb LM2/1, anti-CD47 mAb B2H6 and anti-SIRP antibodies (10µg/ml each, 1h, 4°C), respec-
tively. After washing, PMN were briefly fixed with 3% paraformaldehyde (PF) for 5 min at 25°C 
followed by incubation with fluorescence conjugated secondary antibodies (1:1000 dilution in 
blocking solution) for 30 min. Cells were observed under confocal microscope (Zeiss) or ana-
lyzed by flow cytometry (BD). Cell surface labeling by various antibodies was compared with 
that
 
obtained with isotype-matched control IgG. For intracellular localization staining, cells were 
fixed with 3% PF and then permeabilized by 0.03% Triton X-100 for 10 min at 4
o
C before anti-
body labeling. For plasma membrane labeling, cells were incubated with wheat germ agglutinin 
(WGA) at the final concentration of 5 μg/mL for 1 min at 25 oC followed by washing with HBSS 
(-).  
 
2.12. Other reagents 
Hybridoma cell line that produces anti-CD11b antibody LM2/1 was obtained from the American 
Type Culture Collection (ATCC). Monoclonal antibody against the extracellular domain of 
CD47 (PF3.1) was generated previously [69]. Rabbit polyclonal antibodies against the extracel-
lular domains of SIRPα (anti-SIRPα.ex) and JAM-A (anti-JAM-A.ex) were raised by immuniz-
ing rabbits with purified fusion proteins comprised of rabbit Fc and the entire extracellular do-
mains of SIRPα or JAM-A[87, 203]. Antibodies against Ral, Ras and Rap1 were purchased from 
Millipore. Anti-β actin mAb was purchased from Sigma. Rabbit anti-α-adaptin was purchased 
from Santa Cruz Biotechnology. Rabbit anti-RalGDS was purchased from EMD Millipore.  
Alexa Fluor 594 conjugated WGA was purchased from Invitrogen.  
61 
 
2.13 Statistical analyses 
All the data was analyzed using Prism software. P value for statistical significance was below  
0.05. 
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CHAPTER III: 
CONTROL OF SECONDARY GRANULE RELEASE IN 
NEUTROPHILS BY RAL GTPASE 
 
 
 
 
 
 
 
 
 
PUBLICATION: CHEN CX, SOTO I, GUO YL, LIU Y. CONTROL OF SECONDARY 
GRANULE RELEASE IN NEUTROPHILS BY RAL GTPASE. J BIOL CHEM, 2011 APR 
1; 286(13): 11724-33.  
NOTE:  
I PERFORMED ALL OF THE EXPERIMENTS IN THIS CHAPTER, EXCEPT FOR TABLE 
1.  
DR. YUAN LIU AND I PERFORMED THE EXPERIMENTS SHOWN IN FIGURE 3-1. 
DR. YAUN LIU AND I PERFORMED THE EXPERIMENTS SHOWN IN FIGURE 3-2. 
YAN-LAN GUO AND I PERFORMED THE EXPERIMENT SHOWN IN FIGURE 3-3 and 3-
4. 
DR. YUAN LIU PERFORMED THE EXPERIMENTS FOR FIGURE 4-2A. 
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Introduction 
Neutrophils, or polymorphonuclear leukocytes (PMN), occupy the largest population in 
peripheral leukocytes and play a crucial role in innate immunity. During acute infection and 
inflammation, PMN sense chemoattractant signals and swiftly migrate across the 
microvasculature and underlying tissues to accumulate at inflammatory foci, where these cells 
execute forceful antimicrobial and tissue damaging functions. Therefore, the timely and precise 
response of PMN constitutes an essential first-line defense against invading microbial. On the 
other hand, PMN-mediated inflammation is also a central component of many 
pathophysiological processes and diseases in which dysregulated PMN transmigration and 
activation often result in severe tissue injuries and organ dysfunction [25, 96] 
 
Different from most of other cell types, PMN contain a highly granular cytoplasm. At least four 
types of granules and vesicles have been classified in PMN including peroxidase-positive 
primary granules (also termed azurophil granules), peroxidase-negative secondary and tertiary 
granules (also termed as specific and gelatinase granules, respectively), and a group of highly 
mobilizable secretory vesicles [61-62]. These various granules and vesicles in PMN constitute an 
important reservoir of antimicrobial peptides, proteases, respiratory burst oxidases, as well as 
many membrane-bound receptors and adhesion molecules. PMN functions in response to 
inflammatory stimuli are largely dependent on the mobilization and release (degranulation) of 
these cytoplasmic granules and vesicles. In general, the secretory vesicles are highly mobilized 
for extracellular release. These vesicles provide the PMN cell surface with essential, but low 
levels of receptors and molecules that are important in PMN sensing and triggering activation 
[61-63]. Upon chemoattractant stimulation, secondary and tertiary granules are released, and this 
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vital degranulation process enables PMN to adhere to and migrate across vascular endothelium 
and tissue layers [26, 61-64]. PMN secondary granules contain a large number of key cell 
adhesion molecules, such as the β2 integrin CD11b/CD18 [66-67] and the Ig superfamily 
members CD47 and SIRPα [68-70], all of which are required for PMN adhesion and chemotaxis. 
Degranulation of secondary granules also releases the anti-pathogen protein lactoferrin. Tertiary 
granules have a high content of gelatinases; release of these collagenolytic metalloproteases 
plays a critical role in degradation of the extracellular matrix during PMN extravasation. In 
addition to these granules / vesicles, studies have also found that certain primary granules are 
also released during PMN activation and that some of the primary granule components, such as 
elastase, are indispensable for PMN migration in the tissues. 
 
The molecular mechanisms that control PMN degranulation are, however, still unclear. The sig-
naling events elicited by chemoattractant stimulation leading to PMN degranulation of each type 
of granule are complex, and only inadequately understood. In other cell types, Ras family small 
GTPase Ral has been shown to be required in intracellular vesicle transportation, including both 
endocytosis and exocytosis [117-121]. Here, we report our experimental findings which reveal 
for the first time that Ral controls PMN release of secondary granules.  In particular, our studies 
suggest that active Ral serves as an essential gatekeeper which prevents secondary granule re-
lease. Disruption of Ral regulation, either by inhibition of Ral activity in resting PMN or over-
expression of a constitutively active Ral during chemoattractant stimulation, results in dysregula-
tion of secondary granule mobilization and impairment of PMN chemotactic function. 
 
Results 
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Ras family inhibitor damnacanthal triggeres release of PMN secondary granules. 
PMN surface adhesive proteins, such as CD47 [69, 71], CD11b/CD18 [66-67] and SIRPα [68, 
204], play important roles in PMN adhesion, transmigration and phagocytosis. Instead of being 
constitutively expressed on the cell surface, these essential proteins are mainly stored in intracel-
lular granules under resting conditions, but are rapidly upregulated onto the cell surface in re-
sponse to inflammatory chemoattractants following the process of PMN degranulation [69-70]. 
To reveal the mechanisms involved in control of PMN storage of these important cell surface 
proteins and PMN degranulation, a panel of pharmacological probes / inhibitors targeted differ-
ent signaling molecules and pathways were tested for their effects on the cell surface protein ex-
pression. Treatment of PMN with damnacanthal, a membrane-permeable inhibitor of the Ras 
family GTPases and the Src family tyrosine kinase Lck [205-207], was found to result in a dra-
matic increase of CD11b/CD18, CD47 and SIRPα on the PMN cell surface despite the lack of 
chemoattractant stimulation. As shown in Table 1, after damnacanthal treatment, FACS analysis 
showed increases of the mean fluorescence intensities (MFI) of cell surface CD11b/CD18, CD47 
and SIRPα labeling from the basal level of 90.7, 35.2 and 14.2 up to 203.8, 112.8 and 67.8, re-
spectively. In contrast, treating PMN with the vehicle control or other inhibitors, such as geniste-
in, piceatannol, LFM-A13, PP1, PD98059, LY294002 and others, did not change the levels of 
these proteins on PMN cell surface. Analysis of the cell shape and/or sizes by FSC and SSC pa-
rameters also indicated a visible shift of the PMN population towards lower FSC/SSC after dam-
nacanthal treatment (data not shown), suggesting a potential of PMN degranulation. 
 
Since PMN contain multiple types of intracellular granules, and CD47, CD11b/CD18 and SIRPα 
are mainly stored in secondary granules [69-70], it was thus highly possible that increase of these 
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proteins on the cell surface by damnacanthal treatment was through PMN degranulation. There-
fore, the release of primary, secondary and tertiary granules after damnacanthal treatment was 
analyzed. As shown in Figure 3-1, compared to other inhibitors that did not cause PMN degranu-
lation, damnacanthal dose-dependently induced PMN release of secondary granules. In contrast, 
no apparent release of primary or tertiary granules was observed by treating PMN with damna-
canthal. In the experiments, PMN were also treated with chemoattractant fMLF and a combina-
tion of fMLF and actin filament disruption reagent cytochalasin B (CB) to serve as positive de-
granulation controls [135]. As shown in Figure 3-1, as predicted, treating PMN with only fMLF 
resulted in significant degranulation of secondary and tertiary granules, but not primary granules, 
while treatment with fMLF-CB combination induced a robust and complete degranulation of all 
the granules. At a concentration of 18μM, damnacanthal treatment could generate amounts of 
lactoferrin release comparable to the combined fMLF and CB treatment, indicating a nearly 
complete degranulation of secondary granules (Figure 3-1). In conclusion, these studies found 
that treatment of PMN with damnacanthal selectively induced the degranulation of secondary 
granules. 
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Table 1. Damnacanthal treatment induces an upregulation of CD11b/CD18, CD47 and SIRPα on 
PMN surface.  
Effects of pharmacological inhibitors on PMN cell surface protein expression 
 
  PMN surface mean fluorescence intensity (MFI) 
Inhibitors                        Ctl IgG              CD11b/CD18             CD47                  SIRPα  
 
 
Vehicle ctl (DMSO) 3.2±0.08         90.7±0.11 35.2±0.038        14.2±0.09 
Damnacanthal (10µM)              2.5±0.18         203.8±0.22        112.8±0.19         67.8±0.16 
Genistein (100µg/ml)                  4.3± 0.13        76.6±0.28 30.0±0.13          19.6±0.14 
Piceatannol (40µM) 5.5±0.26         94.0±0.17         28.2±0.14          13.5±0.16 
PP1 (18µM) 2.7±0.33         85.2±0.43 29.3±0.46          11.6±0.31 
LFM-A13 (140µM) 4.4±0.51         89.3±0.44 28.5±0.69           9.7±0.42 
Herbimycin A (2µM)       5.2±0.26         95.7±0.25         30.3±0.15           16.3±0.45 
Lavendustin A (10µM) 5.5±0.16         91.4±0.32 32.2±0.21          20.1±0.25 
Erbstatin analog (25µM)             4.8±0.17          81.6±0.20 29.8±0.19          18.3±0.23 
SB203580 (1µM) 6.1±0.30         83.8±0.40 28.8±0.15          15.2±0.23 
PD98059 (80nM) 3.7±0.16         89.9±0.24          26.7±0.18         12.5±0.25 
LY294002 (100nM)  3.0±0.14         79.6±0.13 31.9±0.30          19.1±0.15 
AG126 (150µM) 4.3±0.17  97. ±0.19 30.7±0.14          14.6±0.24 
 
 
Table 1. In these experiments, freshly isolated PMN (5×10
6
) were incubated with damnacanthal 
or other inhibitors in their working concentrations for 15min at 25°C. After blocking with
 
5% 
normal goat serum, PMN cell surface CD11b, CD47 and SIRPα were labeled with LM2/1, PF3.1 
(10µg/ml each) and anti-SIRPα.ex (1:2000 dilution), respectively, for 1h (4oC). After washing 
and fixation with 3% paraformaldehyde (5min, 20
o
C), cells were incubated with Alexa Fluor-
conjugated secondary antibodies followed by washing and analysis by flow cytometry. PMN la-
beled with normal mouse IgG served as baseline. The table shows the mean fluorescence intensi-
ty ±SEM. SEM: SD divided by the square root of the sample size. 
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Figure 3-1. Damnacanthal treatment induces specific release of PMN secondary granules. Fresh-
ly isolated PMN were treated with damnacanthal (Damn) of varied concentrations and other in-
hibitors for 15min at 25°C.  A control treatment was performed using vehicle (DMSO) of the 
same dilution (0.1%). After centrifugation to pellet cells, PMN degranulation was assessed by 
assaying different granular markers in the cell-free supernatants. Positive degranulation controls 
were performed by stimulation of PMN with 1µM fMLF with and without an addition of 10µM 
cytochalasin B (CB). Concentrations of LY94002, Piceatannol, SB203580, genistein and 
PD98059 used in the treatment were the same as those in Table 1. A) Assaying secondary gra-
nule release by measuring lactoferrin in the supernatants. B) Assaying primary granule release by 
measuring MPO activity in the supernatants. C) Assaying tertiary granule release by zymogram 
detecting gelatinase in the supernatants. The arrows indicate the two major forms of gelatinase 
(92kD and 56kD, respectively) in PMN. As shown, damnacanthal (Damn.) specifically and dose-
dependently induced secondary granule degranulation. Data (mean ± SD) represent more than 
five independent experiments. Significant degranulation was marked by “*”. 
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Damnacanthal treatment results in defect of PMN function.  
In general, PMN degranulation of secondary granules is triggered by chemoattractants binding to 
the cell surface receptors followed by signaling relays involving G protein and a series of down-
stream signaling molecules [208]. Since damnacanthal caused release of secondary granules in 
the absence of chemoattractant stimulation, I questioned whether this kind of “dysregulated” de-
granulation would affect PMN function and thus assayed chemoattractant-induced PMN trans-
migration and adhesion/spreading. As shown in Figure 3-2, in contrast to that PMN vigorously 
transmigrated towards fMLF in the control condition, damnacanthal dose-dependently inhibited 
PMN transmigration and completely abolished PMN migration at a concentration of 18μM. Also 
as shown in Figure 3-3A, compared to control PMN which responded to fMLF stimulation and 
quickly spread on collagen-coated surfaces displaying a polarized F-actin labeling pattern, dam-
nacanthal treatment impaired PMN spreading. Indeed, PMN adhesion to collagen induced by 
fMLF was significantly weakened in the presence of damnacanthal (Figure 3-3B). Next I ex-
amined whether damnacanthal treatment affected cell surface protein function. Since CD47 and 
SIRPα are extracellular counter-ligands [68, 87], we thus tested cell surface CD47 direct binding 
to a SIRPα extracellular domain fusion protein, SIRPα1.ex-Fc [70, 87]. As shown in Figure 3-4, 
although damnacanthal induced a significant increase of CD47 on PMN cell surface, these upre-
gulated CD47 were not binding to its ligand SIRPα. In contrast, CD47 was also increased on 
PMN surface after fMLF stimulation, and these CD47 directly bound to SIRPα1.ex-Fc (Figure 3-
4). 
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Figure 3-2. Damnacanthal inhibits chemoattractant-triggered PMN function. A) Damnacanthal 
inhibits PMN chemotaxis. PMN (10
6
) were treated with damnacanthal of varying concentrations 
for 15min at 25°C followed by assaying transmigration across collagen-coated filters towards 
fMLF (0.1µM) in 1h. Data (mean ± SD) represent three independent experiments with triplicates 
in each condition (*, p<0.05, **, p<0.01).   
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Figure 3-3.  Damnacanthal inhibits chemoattractant-triggered PMN function. Damnacanthal in-
hibits PMN F-actin polarization (A) and spreading (B). PMN (10
6
), untreated or treated with  
damnacanthal (10 µM), were stimulated with fMLF (1µM, 37°C) in collagen-coated wells fol-
lowed by observation of PMN adhesion and spreading (phase-contrast images). After stimulation 
for 20min, the cells were then fixed and permeabilized followed by labeling F-actin with rhoda-
mine-conjugated phalloidin.  
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Figure 3-4. Damnacanthal inhibits chemoattractant-triggered PMN function. Cell surface CD47 
binding to SIRPα. An extracellular domain fusion protein, SIRPα1.ex-Fc, was used to test PMN 
cell surface CD47 binding after treatment with either fMLF (1µM) or damnacanthal (10µM). To-
tal amount of CD47 on cell surface was confirmed by labeling non-permeabilized cells with anti-
CD47 mAb PF3.1.  
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Identification of the specific GTPase associated with secondary granule release.  
Efforts have been made to identify the target molecule of damnacanthal that plays an important 
role in preventing secondary granule release in PMN prior to chemoattractant stimulation. We 
have found that, although damnacanthal is a potent inhibitor of the tyrosine kinase Lck, its effect 
on PMN degranulation was not through targeting Lck. In agreement with many studies by others, 
I observed that Lck is mainly expressed in T cells but not in PMN (Figure 3-5). In addition, Dr. 
Liu obtained Lck-knockout mice [209] from Dr. Tak Mak (Ontario Cancer Institute, Canada). 
Comparing PMN isolated from Lck knockout mice with the cells from their wild-type littermates 
yielded no difference in the levels of cell surface protein expression, PMN response to chemoat-
tractant stimulation, degranulation and chemotactic transmigration (data not shown), suggesting 
that Lck is dispensable in PMN function. A previous study by Brumell et al. also indicated no 
Lck activity in PMN[210]. In addition to Lck, damnacanthal is also an established inhibitor of 
Ras family small GTPases [206-207]. Since some of these GTPases, such Ras family member 
Ral, have been demonstrated to play important roles in vesicle transportation, thus it was likely 
that the effect of damnacanthal on PMN through inhibition of Ras family members.  
 
The Ras family small GTPases are traditionally classified into three major subfamilies, Ras (H, 
R, etc.), Rap (1/2) and Ral (A/B) [211-213]. In addition, three new members of Ras family small 
GTPases have been identified recently including Rheb, Rin, and Rit [214]. To identify which is 
potentially involved in the degranulation of secondary granules, I screened the Ras members for 
activity changes before and after chemoattractant stimulation. Given that damnacanthal treatment 
caused secondary granule release in the absence of stimulation, I speculated that the candidate 
Ras member must be in its active form in resting PMN. Also, since chemoattractant stimulation 
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triggers secondary granule release, we reasoned that this specific Ras should be deactivated in 
order to coordinate secondary granule release. Based on this rationale, I assayed the activities of 
Ras, Rap and Ral in PMN before and after fMLF stimulation, and with or without damnacanthal 
treatment. As shown in Figure 3-6, Ras, Rap and Ral were all expressed in PMN. Among the 
three family members, Ras was found mainly in its inactive form in unstimulated PMN and was 
quickly activated after fMLF stimulation. Rap, on the other hand, showed minor activity changes 
before or after fMLF stimulation and, to our surprise, was insensitive to damnacanthal treatment 
(Figure 3-6). Therefore, neither Ras nor Rap was likely the candidate that regulates secondary 
granule release. 
 
In contrast to Ras and Rap, Ral demonstrated a dynamic activity change that correlated with 
chemoattractant stimulation and PMN degranulation. As shown in Figure 3-6, Ral appeared to be 
in its active form in unstimulated PMN, and quickly became inactive following fMLF stimula-
tion. Pull-down experiments using RalBP1, a downstream effector that specifically binds to ac-
tive Ral, recovered significant amount of active Ral from resting PMN. On the other hand, stimu-
lation with fMLF resulted in a quick diminishing of RalBP1 pull-down within 2-5min, a time 
course paralleled with secondary granule release that was assayed simultaneously (Figure 3-6, 
right). Same results of were obtained when PMN were stimulated by another chemoattractant IL-
8 (Figure 3-7). Deactivation of Ral was also observed in PMN that had chemotactically transmi-
grated across collaged-coated filters towards fMLF (Figure 3-6, migrated). In addition, activity 
of Ral in resting PMN was inhibited after damnacanthal treatment (Figure 3-6), which correlated 
with damnacanthal-induced secondary granule release. Thus, these results suggested Ral to be 
the regulator that controls secondary granule release in PMN.    
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Figure 3-5. Lck is not expressed in neutrophils (PMN). A) Western blot detecting Lck in PMN 
and PBMC. B) Immunofluorescence labeling demonstrating that Lck is expressed in SIRPα-
negative cells in PBMC, mainly lymphocytes, but not in SIRPα-positive monocytes or PMN. 
(Antibody against Lck was purchased from Cell Signaling Technology.)  Note: SIRPα is re-
stricted in myeloid lineages, including PMN, monocytes and dendritic cells, but not expressed in 
lymphocytes. Few Lck-positive cells detected in isolated PMN were likely due to an unavoidable 
contamination of PBMC. In general, PMN are separated from PBMC by Ficoll-Paque density 
gradient (used for this study) or gelatin sedimentation.  The former method normally produces 
PMN of 90-95% purity while the latter method produces PMN of varied purity, between 70-
90%. Expression of Lck in eosinophils was also reported (Stafford et al. The Journal of Immu-
nology, 2002; Lynch et al. Blood, 2000) and may account for few Lck-positive cells in the prepa-
ration of PMN. 
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To further explore the mechanism that regulates Ral activity in PMN, the localization of RalGDS 
in PMN was investigated (Figure 4-1). The effect of Ca
2+
 and Mg
2+
 on Ral activity was ex-
amined (Figure 4-2, 4-3, 4-4). Results showed that Mg
2+ 
was the potential regulator in control-
ling Ral activity. 
 
To confirm my studies in PMN and verify the pull-down assays, in parallel experiments, I simul-
taneously assayed Ral activity in platelets.  As shown in Figure 3-7B, RalBP1 pull-down results 
agreed with the previous report by others showing that Ral is inactive in  resting platelets and 
activated after thrombin stimulation [163]. The different Ral activity profiles in PMN and plate-
lets thus suggest that these cells employ distinctive signaling mechanisms to regulate Ral activity 
and that Ral may have different functional aspects in PMN and platelets. 
 
In addition, Ral activity was also assayed in PMN isolated directly from the “buffy coat” (Figure 
3-8) or isolated using lympholyte-poly (Figure 3-9, Figure 3-10) to further investigate the effects 
of Ral activity on PMN secondary granule release.  
 
Comparing PMN isolated using DEAE-DEXTRAN with the cells isolated from the “buffy coat”, 
Ral demonstrated the same activity profile. As shown in Figure 3-8, Ral was in its active form in 
unstimulated PMN, and became inactive following fMLF stimulation.  
 
Ral in PMN isolated using commercial separation chemical, lympholyte-poly, however, retained 
minimal activity in unstimulated cells (Figure 3-9 and Figure 3-10). fMLF stimulation (Figure 3-
9) rendered a quick activation of Ral within 1 min, and a prompt diminishment of Ral activity 
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after 1 min. IL-8 stimulation (Figure 3-10), on the other hand, sustained Ral activity until 10 min, 
followed by the loss of activity after 15 min. The similar observation that Ral was inactive in un-
stimulated PMN was reported by another group [215]. The variation of Ral activity in unstimu-
lated PMN was likely due to the distinct isolation method. In my study, I employed three isola-
tion approaches to examine the activity of Ral in PMN before and after chemoattractant stimula-
tion. Ral was only shown to be inactive in PMN isolated using lympholyte-poly. The results sug-
gest that PMN isolated using DEAE-DEXTRAN may not represent the native status of PMN in 
the blood stream. Nonetheless, Ral lost activity following chemoattractant stimulation in PMN 
isolated using different methods, and Ral deactivation with time courses correlated with second-
ary granule release induced by either fMLF or IL-8. Thus, the results strongly suggest that Ral is 
likely the specific GTPase that regulates PMN granule mobilization, and in particular, plays an 
important role in controlling secondary granule release from PMN. Deactivation of Ral is like-
wise essential for PMN secondary granule release. 
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Figure 3-6. Ral deactivation correlates secondary granule release in PMN. Detecting activity 
changes of Ras family small GTPases including Ral, Ras and Rap in PMN. After time-course 
stimulation with fMLF (1µM), PMN were lysed and active Ras, Ral and Rap were pulled down 
using Raf-1 RBD, RalBP1 and RalGDS-RBD, respectively. In parallel, fMLF-induced PMN de-
granulation of secondary granules was assayed simultaneously by detecting lactoferrin in the 
cell-free supernatants (right panel). PMN that transmigrated across collagen-coated filters into 
the fMLF-containing lower chambers, or treated with damnacanthal were also assayed for active 
Ral, Ras and Rap. Cell lysates before pull-down were used to detect total Ral, Ras and Rap, as 
well as actin using antibodies against Ral, Ras, Rap and β actin.  
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Figure 3-7. Ral deactivation correlates secondary granule release in PMN. A) Deactivation of 
Ral by IL-8 stimulation. Recombinant IL-8 (0.4µg/ml) (Sigma) was used to stimulate PMN for 
different time periods followed by RalBP1 pull-down to detect active Ral. B) Ral activities in 
unstimulated and thrombin (0.1U/ml) (Sigma)-stimulated platelets.  
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Figure 3-8. Detecting activity changes of Ral in PMN isolated directly from “buffy coat”. After 
time-course stimulation with fMLF (1µM), PMN were lysed and active Ral was pulled down us-
ing RalBP1.  
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Figure 3-9. Ral deactivation correlates secondary granule release in PMN. Detecting activity 
changes of Ral in PMN isolated using lympholyte-poly. After time-course stimulation with 
fMLF (1µM), PMN were lysed and active Ral was pulled downed using RalBP1. In parallel, 
fMLF-induced PMN degranulation of secondary granules was assayed simultaneously by detect-
ing lactoferrin in the cell-free supernatants (right panel). All the posts were significantly higher 
than unstimulated (One-way ANOVA, repeated measures, p<0.0001 with Dunnett’s post tests) * 
indicates significant differences (p<0.05). 
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Figure 3-10. Ral deactivation correlates secondary granule release in PMN. Detecting activity 
changes of Ral in PMN isolated using lympholyte-poly. After time-course stimulation with re-
combinant IL-8 (0.4µg/ml) (Sigma), PMN were lysed and active Ral was pulled downed using 
RalBP1. In parallel, fMLF-induced PMN degranulation of secondary granules was assayed si-
multaneously by detecting lactoferrin in the cell-free supernatants (right panel). All the posts 
were significantly higher than unstimulated (One-way ANOVA, repeated measures, p<0.0001 
with Dunnett’s post tests) * indicates significant differences (p<0.05). 
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Active Ral blocks secondary granule release in PMN.  
To test that active Ral in resting PMN serves to prevent secondary granule release and that Ral 
deactivation in response to chemoattractant stimulation is required for degranulation, I designed 
experiments to over-express a constitutively active Ral, Ral23V, in PMN and tested its effect on 
fMLF-induced degranulation. Since freshly isolated PMN are short-lived and not suitable for 
protein expression by conventional gene transfection methods, I employed protein transduction 
technology and directly delivered purified recombinant Ral into PMN by tagging the proteins 
with an HIV Tat peptide (YGRKKRRQRRR) [54, 200, 216]. As demonstrated by previous stu-
dies, HIV Tat and other poly-arginine peptides have been widely used to transduce proteins of up 
to 120kD into live cells [54, 200, 216] . Although PMN are highly sensitive and difficult to han-
dle, using HIV Tat to study important intracellular molecules has been very successful [54, 217-
218]. In this study, three Tat-tagged Ral proteins were generated, including a wild-type Ral 
(WT), a constitutively active mutant Ral (Ral23V), and a dominant negative mutant Ral 
(Ral28N) [117, 167, 202]. As depicted in Figure 3-11, these proteins were first produced as re-
combinant GST fusions, followed by removal of GST and yielding Tat-tagged Ral. Figure 3-
11B&C shows the stepwise production of Tat-tagged WT, Ral23V and Ral28N, and RalBP1 
pull-down confirming that Ral23V was a constitutively active form.  
 
To determine that Tat-tagged Ral proteins were capable of directly delivery into PMN, I chemi-
cally labeled the purified proteins with fluorescein (FITC), followed by incubation with PMN. 
As shown in Figure 3-12A, fluorescence microscopy revealed that the three Tat-tagged Ral pro-
teins (Tat-WT, Tat-Ral23V and Tat-Ral28N) were all rapidly delivered into PMN after only a 
short incubation (10min) at a low temperature (4°C).  Subsequent Western blot detected an over 
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two-folds increase of Ral in PMN after incubating with each Tat-tagged Ral protein (Figure 3-
12B). I also performed RalBP1 pull-down assays to test Ral activity after delivery of each Tat-
tagged Ral protein into PMN. As shown in Figure 3-13, transduction of exogenous Ral23V into 
PMN led to a sustained Ral activity in PMN even in the presence of fMLF stimulation, a condi-
tion that the endogenous Ral activity was completely diminished as that observed in the control, 
non-peptide transduction PMN. Transduction of WT Ral or Ral28N, on the other hand, only 
slightly (WT) or did not (Ral28N) increase Ral activity in PMN (Figure 3-13).   
 
I next investigated whether Ral activity blocks fMLF-induced PMN degranulation. In these ex-
periments, PMN were first loaded with Tat-tagged WT Ral, Ral23V or Ral28N, and then stimu-
lated with fMLF.  As shown in Figure 3-14A, no spontaneous PMN degranulation was detected 
by just loading Tat-tagged Ral proteins (unstimulated). Prominent release of secondary granules 
was induced by fMLF in PMN loaded with WT Ral or Ral28N, or without peptide delivery. On 
the contrary, transduction of the constitutively active Ral, Ral23V, into PMN strikingly blocked 
secondary granule release in the presence of fMLF. As shown in Figure 3-14, both lactoferrin 
release (Figure 3-14A) and CD47 translocation to the cell surface plasma membrane (Figure 3-
14B) were inhibited by Ral23V in PMN in spite of fMLF stimulation. However, Ral23V had no 
effect on fMLF-induced tertiary granule release or the retention of primary granules (Figure 3-
15A), further suggesting that Ral selectively regulates secondary granule mobilization.   
 
Given that PMN degranulation of secondary granules is crucial for chemotaxis, I thus performed 
PMN transmigration assays and examined the effect of Ral23V. As shown in Figure 3-15B, as 
expected, transduction of Ral23V into PMN significantly reduced PMN transmigration towards 
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fMLF, while WT Ral or Ral28N had no inhibition. In conclusion, these results demonstrated that 
Ral activity blocks secondary granule release from PMN. Therefore chemoattractant-induced Ral 
deactivation is essential for PMN degranulation, activation and chemotaxis.   
 
In order to further investigate whether active Ral inhibits fMLF-induced PMN secondary granule 
release regardless of what PMN isolation method is employed, transduction of Tat-tagged consti-
tutively active Ral (Ral23V) into PMN isolated from “buffy coat” or using lympholyte-poly fol-
lowed by assay of secondary granule release was carried out. In these experiments, PMN were 
first loaded with Tat-tagged WT Ral, Ral23V or Ral28N, and then stimulated with fMLF.  As 
shown in Figure 3-16, 3-17, and 3-18, transduction of the constitutively active Ral, Ral23V, not-
ably blocked both CD47 translocation to the cell surface plasma membrane (Figure 3-16 and 
Figure 3-17) and lactoferrin release (Figure 3-18) regardless of fMLF stimulation. Overexpres-
sion of active Ral in PMN isolated from the “buffy coat”, using lympholyte-poly, or using 
DEAE-DEXTRAN prevented secondary granule release, thus, further supporting the fact that 
active Ral serves as a gate-keeper for degranulation of secondary granules from PMN.  
 
Considering that the Ral gene is composed of RalA and RalB, I further explored the role of the 
Ral gene in human PMN. As shown in Figure 3-19, studies of Ral expression in human leuko-
cytes by RT-PCR detected both RalA and RalB in PMN. RalA and RalB are highly homologous 
proteins and share most (if not all) of the functional domains identified to date, as shown in Fig-
ure 1-11 and Figure 1-12. The possible Ral downstream effector proteins relevant to our study 
involved in receptor endocytosis, such as RalBP1/RLIP76, were found to bind to RalA and RalB 
at sites with an identical amino acid sequence (aa 37-56). Although RalA and RalB have over-
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lapping functions, which have been reported by various studies, I further investigated the specific 
role of RalB in PMN secondary granule release. In these experiments, I generated a Tat-tagged 
constitutively active RalB (RalB23V) protein, followed by transduction of the protein into PMN, 
and assayed its effect on secondary granule release. Transduction of RalB23V into PMN also 
inhibited PMN mobilization of secondary granules shown by impaired lactoferrin release and 
blockage of CD47 translocation to plasma membrane (Figure 3-20).   
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Figure 3-11. Generation of Tat-tagged wild-type Ral (WT), constitutively active Ral (Ral23V), 
and dominant negative Ral (28N) protein. A) A schematic depiction of Tat-tagged Ral produc-
tion. The recombinant fusion proteins containing GST and Tat-Ral were produced, followed by 
cleavage of GST with Factor Xa to yield Tat-Ral peptides. The figure also shows that two point 
mutations, G23V and S28N, were created in Ral to produce constitutively active Ral (23V) and 
dominant negative Ral (28N). B) A stepwise analysis of Tat-tagged Ral protein production by 
SDS-PAGE and Coomassie blue staining. C) RalBP1 pull-down confirming that Tat-Ral23V was 
a constitutively active GTPase. Purified Tat-tagged wild-type Ral, Ral23V and Ral28N (0.2µg 
each) were incubated with GST-RalBP1 (1µg) and glutathione Sepharose in HBSS containing 
5% non-fat dry milk, 2% BSA and 0.01% Tween 20 for 1h. After washing the precipitates, 
Western blot was performed to detect active Ral pulled down by RalBP1. 
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Figure 3-12. Transduction of Tat-tagged Ral proteins including wild-type Ral (WT), constitu-
tively active Ral (Ral23V), and dominant negative Ral (28N) to PMN. A) Assaying Tat-tagged 
Ral transduction into PMN. Tat-tagged wild-type Ral (WT), Ral23V and Ral28N (0.1µM of 
each) were labeled with FITC followed by incubation with PMN for 10min at 4°C. B) Effective 
transduction into PMN was then analyzed by Western blot. 
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Figure 3-13. Tat-tagged constitutively active Ral sustained endogenous Ral activity in PMN. 
After transduction of Tat-tagged Ral into PMN, PMN were stimulated with fMLF (1µM) for 
20min at 37°C followed by cell lysis. RalBP1 pull-down were then performed to detect active 
Ral. As shown, the result confirmed that transduction of Ral23V in PMN resulted in a sustained 
Ral activity even with fMLF stimulation. 
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Figure 3-14. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary 
granule release in PMN.  A) & B) Effects of Tat-tagged Ral proteins on fMLF-induced second-
ary granule release in PMN. PMN were incubated with purified Tat-tagged wild-type Ral (WT), 
the constitutive active Ral (Ral23V) and dominant negative Ral (Ral28N) at concentrations of 
10nM and 40nM, or control buffer (No peptide) (30min, 4°C) followed by stimulation with 
fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was analyzed by measur-
ing lactoferrin release in the cell-free supernatants (A) and cell surface labeling of CD47 by anti-
CD47 antibody PF3.1 (B) followed by flow cytometry (FACS). The data were subjected to a 
one-way ANOVA (repeated measures, p<0.0001 with Dunnett’s post tests). * indicates signifi-
cant differences in lactoferrin release from PMN with and without Tat-Ral23V transduction   (p 
<0.05). 
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Figure 3-15. Specificity of Tat-tagged Ral proteins in PMN granule release. A) Tat-Ral23V has 
no effect on the mobilization of primary and tertiary granules. B) Transduction of Tat-Ral23V 
into PMN inhibited PMN chemotactic transmigration. Data (mean ± SD) represent three inde-
pendent experiments with triplicates in each condition. The data were subjected to a one-way 
ANOVA (repeated measures, p<0.0001 with Dunnett’s post tests). * indicates significant differ-
ences in cell number of migrated PMN with and without Tat-Ral23V transduction   (p <0.05) 
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Figure 3-16. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary 
granule release in PMN isolated using lympholyte-poly. PMN were incubated with purified Tat-
tagged wild-type Ral (WT), the constitutive active Ral (Ral23V) and dominant negative Ral 
(Ral28N) at concentration of 40nM, or control buffer (No peptide) (30min, 4°C) followed by 
stimulation with fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was ana-
lyzed by cell surface labeling of CD47 by anti-CD47 antibody PF3.1 (right panel) followed by 
flow cytometry (FACS) (left panel).  
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Figure 3-17. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary 
granule release in PMN isolated directly from “buffy coat”. PMN were incubated with purified 
Tat-tagged wild-type Ral (WT), the constitutive active Ral (Ral23V) and dominant negative Ral 
(Ral28N) at concentration of 40nM, or control buffer (No peptide) (30min, 4°C) followed by 
stimulation with fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was ana-
lyzed by cell surface labeling of CD47 by anti-CD47 antibody PF3.1 (right panel) followed by 
flow cytometry (FACS) (left panel).  
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Figure 3-18. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary 
granule release in PMN isolated from “buffy coat” (A) and using lympholyte-poly (B).  A) & B) 
Effects of Tat-tagged Ral proteins on fMLF-induced secondary granule release in PMN. PMN 
were incubated with purified Tat-tagged wild-type Ral (WT), the constitutive active Ral 
(Ral23V) and dominant negative Ral (Ral28N) at concentration of 40nM, or control buffer (No 
peptide) (30min, 4°C) followed by stimulation with fMLF (1µM) for 20min at 37°C. Degranula-
tion of secondary granules was analyzed by measuring lactoferrin release in the cell-free super-
natants. A) All the posts had significant difference compared with than no peptides (One-way 
ANOVA, repeated measures, p<0.0002 with Dunnett’s post tests) B) All the posts had signifi-
cant difference compared with no peptide treatment (One-way ANOVA, repeated measures, 
p<0.0001 with Dunnett’s post tests) * indicates significant differences in lactoferrin release from 
PMN with and without Tat-Ral23V transduction (p<0.05).  
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Figure 3-19.  Detection of RalA and RalB in human leukocytes. The RalA-specific and the 
RalB-specific cDNA fragments, 777bps and 648bps, respectively, were RT-PCR amplified from 
freshly isolated PMN and PMBC. The same DNA fragments were also PCR amplified from a 
human leukocyte cDNA library (Marathon Ready cDNAs, Clontech). Given that RalA and RlaB 
are highly homologous, the PCR primers were specially chosen based on the most dissimilar re-
gions of their cDNAs. The primers for amplifying RalA were 5-ttccaggcgacaaggaccg agta and 5-
aagataagaaaggagtttggg. The primers for amplifying RalB were 5-atggctgccaacaagagtaag and 5-
agctggcttcatccgtcacctt. The amplified PCR fragments were DNA sequenced to confirm their 
identities. 
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Figure 3-20. Constitutively active RalB (Ral23V) inhibits chemoattractant-induced secondary 
granule release. PMN were incubated with purified Tat-tagged wild-type RalB (WT), the consti-
tutive active RalB (Ral23V) and dominant negative RalB (Ral28N) at concentration of 40nM or 
10nM, or control buffer (No peptide) (30min, 4°C) followed by stimulation with fMLF (1µM) 
for 20min at 37°C. Degranulation of secondary granules was analyzed by lactoferrin release (left 
panel) and cell surface labeling of CD47 by anti-CD47 antibody PF3.1 (right panel). All the 
posts had significant difference compared with no peptide treatment (One-way ANOVA, re-
peated measures, p<0.0001 with Dunnett’s post tests) * indicates significant differences in lacto-
ferrin release from PMN with and without Tat-Ral23V transduction (p<0.05).  
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Ral translocation between plasma membranes and secondary granules  
Like Ras family GTPases, Ral contains a lipid modification site at the carboxyl terminus, sug-
gesting that Ral may be associated with the cell membranes. To test this, I separated PMN mem-
branes from the cytosol by ultracentrifugation in the absence of detergent. As shown in Figure 
10A, Western Blot indicated that Ral is exclusively associated with the cell membranes in PMN. 
To further localize Ral and define whether Ral is dynamically coupled with secondary granules, I 
performed subcellular fractionation using sucrose density gradients. As shown in Figure 3-21, 
the fractionations successfully separated PMN plasma membranes (alkaline phosphatase) from 
secondary granules (lactoferrin) and primary granules (MPO). To my surprise, detection of Ral 
in the fractions by western blots revealed that Ral is entirely associated with the plasma mem-
brane in unstimulated PMN that is co-localized with another plasma membrane protein JAM-A. 
Stimulation with fMLF, on the other hand, resulted in translocation of a considerable amount of 
Ral to secondary granules (Figure 3-21B). In agreement with previous observation [68, 70], pro-
teins initially stored in secondary granules, such as SIRPα, were redistributed to the plasma 
membrane after fMLF stimulation following degranulation. As predicted, RalBP1 pull-down re-
covered active Ral from the plasma membrane fractions of unstimulated PMN, but not from sec-
ondary granule-rich fractions (Figure 3-22). I also performed immunofluorescence labeling and 
observed that, as shown in Figure 3-23, Ral in unstimulated PMN was co-localized with the 
plasma membrane marker wheat germ agglutinin (WGA) [219]. Stimulation with fMLF induced 
a significant dissociation of Ral from WGA, suggesting Ral redistribution in PMN.  
 
One major mechanism of plasma membrane internalization in PMN after chemoattractant stimu-
lation is through clathrin-mediated cell surface receptor endocytosis [208, 220], and a previous 
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study demonstrated that a Ral effector is complexed with a component of clathrin pits [121]. 
Therefore, I examined whether fMLF-induced Ral translocation from the plasma membrane to 
intracellular granules followed this pathway.  
 
Two inhibitors, dynasore [193] and a AP-2 binding Eps15 C-terminal peptide (Eps15-DIII)[194-
195], which specifically act on the clathrin-dependent
 
endocytosis were examined. As shown in 
Figure 3-24A, pre-treatment of PMN with dynasore (80 µM) and recombinant Eps15-DIII (40 
nM), or their combination, appeared to have no inhibition on Ral translocation to secondary gra-
nules after fMLF stimulation. Dynasore inhibits dynamin, an essential GTPase regulating clath-
rin-coated pit fission, while Eps15-DIII inhibits clathrin-mediated endocytosis through sequestra-
tion of AP-2 thus interferes formation of the clathrin coat. To effectively use Eps15-DIII in the 
study, this peptide was tagged with HIV-Tat, which significantly facilitated protein transduction 
into PMN (Figure 3-24B). I also confirmed the function of the Eps15-DIII by protein pull-down 
assays, which demonstrated that Eps15-DIII successfully co-precipitated AP-2 from PMN ly-
sates (Figure 3-24C).  
 
In addition to dynasore and a AP-2 binding Eps15 C-terminal peptide (Eps15-DIII), I also in-
cluded several other traditional endocytosis inhibitors that act on the clathrin-dependent endocy-
tosis including hypertonic sucrose (0.5M)[221], salt (0.76M NaCl)[222], phenylarsine oxide 
(POA)[223], chlorpromazine (CPZ)[196], and cytosolic acidification (succinic acid, pH5.5) 
[197-198]. As shown in Figure 3-25A, blocking clathrin-mediated endocytosis in PMN with 
classical inhibitors resulted in a partial or complete inhibition of fMLF-induced secondary gra-
nule release. Remarkably, as shown in Figure 3-25B, these reagents also abolished Ral deactiva-
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tion after fMLF stimulation. In addition, contrary to the fact that dynasore and the Eps15 peptide 
failed to exhibit inhibitory effects, CPZ and succinic acid remarkably blocked Ral translocation. 
Subcellular fractionations demonstrated that, as shown in Figure 3-24A, blockage of clathrin-
dependent endocytosis by CPZ [196] or cytosolic acidification (succinic acid, pH5.5) through 
inhibition of the pinching off of clathrin-coated pits [197-198] eliminated Ral translocation from 
plasma membranes to secondary granules in response to fMLF. These two inhibitors also effec-
tively blocked fMLF-induced secondary granule release as indicated by a failure of translocation 
of secondary granule proteins (e.g. SIRPα) to the plasma membrane (Figure 3-24A). As pre-
dicted, immunofluorescence labeling revealed a failure of Ral dissociation from the plasma 
membrane marker WGA in the presence of those two endocytic inhibitors (Figure 3-23, lower 
panel). 
 
The results demonstrated that only classical inhibitors including CPZ and succinic acid were able 
to block Ral translocation from plasma membrane to secondary granules upon fMLF stimulation. 
Considering the nonspecificity of classical inhibitors for clathrin-mediated endocytosis, these 
results suggest that clathrin-mediated endocytosis might not be involved in Ral intracellular 
translocation and deactivation.  
 
Considering that Ral deactivation and translation results in PMN secondary granule release, the 
role of Ral in damnacanthal-mediated PMN secondary granule release was explored. Results, 
however, were not conclusive (Figure 4-5, 4-6, 4-7).  
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Figure 3-21.  Localization of Ral in PMN.  A) Ral is associated with membranes. PMN 
(2.5×10
7
) were dounce-lysed followed by ultracentrifugation to separate cytosol from cell mem-
branes. SDS-PAGE and Western blot were performed to detect Ral in the total lysate before cen-
trifugation (total PMN) and in the separated cytosol and membranes. B) Subcellular localization 
of Ral in PMN. PMN (10
8
/per condition), unstimulated and fMLF-stimulated, were lysed and 
subjected to sucrose density gradient centrifugation to separate the plasma membrane and intra-
cellular granules followed by fractionation. Western blots (lower panel) were performed to detect 
Ral, SIRPα and JAM-A in the fractions using antibodies against Ral, anti-SIRPα.ex and anti-
JAM-A.ex. JAM-A is a transmembrane protein consistently expressed in the plasma membranes.  
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Figure 3-22.  In unstimulated PMN, Ral is active in plasma membrane and inactive in secondary 
granules.  PMN (10
8
/per condition) were lysed and subjected to sucrose density gradient centri-
fugation to separate the plasma membrane and intracellular granules followed by fractionation. 
Active Ral was pulled down using RalBP1 from plasma membrane, secondary granules, 1KS 
(dounced lysate in the absence of detergent), and total cell lysate. SDS-PAGE and Western blot 
were performed to detect active Ral using antibody against Ral.  
 
 
 
 
 
 
 
 
Active Ral
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Figure 3-23. Localization of Ral in PMN.  Immunofluorescence labeling of Ral in PMN.  PMN, 
unstimulated and fMLF-stimulated, were fixed and permeabilized with 0.02% Triton X-100.  
After washing and blocking, cells were labeled with anti-Ral antibody (green) and plasma mem-
brane marker wheat germ agglutinin (WGA) (red).   
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Figure 3-24.  Ral translocation from the plasma membrane to secondary granules may follow 
fMLF-induced endocytic process. A) Effect of clathrin-dependent endocytic inhibitors on Ral 
redistribution in PMN. In these experiments, PMN were pre-incubated with dynasore (80µM), 
Tat-tagged Eps15 peptide (Eps15-DIII) (40nM), or a combination of the two reagents for 15min 
(25°C) before fMLF stimulation (20min at 37°C). After cell lysis, subcellular fractionation was 
performed followed by detection of Ral by Western blots. The effect of other endocytosis inhibi-
tors, CPZ (50µM) and succinic acid (20mM, pH5.5), on Ral distribution was also tested.  B) Pro-
tein transduction of Tat-tagged Eps15-DIII into PMN. Purified Tat-tagged Eps15-DIII was fluo-
rescent labeled followed by incubating with PMN for 10min (4°C). The image shows that Eps15-
DIII was successfully delivered into the cells. C) Pull-down assay confirmed that Eps15-DIII di-
rectly binds to AP-2 complexes. PMN (1.5x10
7
) were lysed in a buffer containing 1% Trition X-
100 and protease inhibitors followed by incubation with 10µg purified Tat-tagged Eps15-DIII in 
the form of GST fusion protein or its non-binding control peptide Tat-tagged Eps15-Δ for 3h 
(4°C). After pull-down with glutathione Sepharose, the precipitated protein complexes were 
washed and analyzed by western blot using antibody against α-adaptin, an important component 
of AP-2 complexes. 
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Figure 3-25.  Blockage of clathrin-dependent endocytosis inhibits fMLF-induced secondary gra-
nule release (A), Ral deactivation (B) and Ral translocation (C). In these experiments, PMN were 
incubated with hypertonic solutions (0.5M sucrose and 0.76M NaCl), POA (20µM), CPZ 
(50µM), succinic acid (20mM, pH5.5), or a mixture of later three reagents (combination) for 
5min (25°C) before fMLF stimulation (20min at 37°C). Release of lactoferrin into the superna-
tants was measured (A). Ral activity was detected by RalBP1 pull down assays (B). All the posts 
were significantly lower than HBSS and vehicle control (One-way ANOVA, repeated measures, 
p<0.0001 with Dunnett’s post tests) * indicates significant differences (p<0.05).  There was no 
significant difference between HBSS and vehicle control (p>0.05). 
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CHAPTER IV: 
DISCUSSION 
As a type of highly specialized and fast responsive cells, PMN store a large number of function-
ally important molecules in the intracellular granules and vesicles. Upon stimulation, PMN 
promptly mobilize these granules/vesicles and rapidly release arrays of cell adhesion molecules, 
receptors, and proteases to the cell surfaces to facilitate PMN adhesion, chemotaxis and microbi-
al killing. At least four types of granules and vesicles varied in size/shape and content have been 
identified in PMN [25, 96], but the mechanisms that control their mobilization and release during 
PMN response to inflammatory stimulation remain largely undefined. Among these granules and 
vesicles, secondary granules are defined as being mostly rich in leukocyte integrins and adhesive 
receptor-like proteins. Degranulation of secondary granules thus serves as a major means to fur-
nish the cell surface plasma membrane with the essential cell adhesion and migration molecules. 
Here, we report our studies of PMN degranulation which reveal, for the first time, that the Ras 
family member, Ral, is a critical regulator specifically in the degranulation of secondary gra-
nules.  
 
As shown by my results, Ral exits as an active GTPase in freshly isolated PMN and its activity 
plays a key role in keeping secondary granules in the cell. Inhibition of Ral in resting PMN by 
damnacanthal, a Ras family GTPase inhibitor with unclear mechanism [206-207], causes “pre-
mature” liberation of secondary granules in the absence of chemoattractant stimulation. Howev-
er, this dysregulated degranulation has no benefit to, but instead impeded PMN function. As I 
observed, although damnacanthal increased cell surface integrins and adhesive molecules, these 
upregulated molecules failed to mediate effective PMN interactions, adhesion and migration. In 
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particular, my results (Figure 3-4) showed that, in contrast to fMLF-induced CD47 on the cell 
surface that mediates binding interactions with its extracellular ligand, damnacanthal-induced 
CD47 on PMN were incapable of binding interaction. Similarly, cell surface upregulated 
CD11b/CD18 by damnacanthal did not appear to mediate strong extracellular interactions, which 
count, in part, for the decrease of PMN adhesion and spreading in response to fMLF. Thus, these 
results suggest that a critical mechanism, which is generally elicited by chemoattractant stimula-
tion, is required to control secondary granule degranulation and, along this process, also converts 
essential cell surface proteins to be functional and ready to mediate cell surface interactions. 
These studies thus further signify the important role of Ral in PMN. By preventing irregular de-
granulation in the absence of stimuli, the Ral-mediated mechanism preserves PMN functional 
capability for potent and effective response during inflammation.  
 
In this study, I also obtained the important result that chemoattractant induces a rapid deactiva-
tion of Ral in PMN, which explains a dynamic regulation required for secondary granule release. 
In contrast, experimentally over-expression of a constitutively active Ral, Ral23V [117, 167, 
202], into PMN to sustain Ral activity even in the presence of fMLF resulted in prohibition of 
secondary granule release, and hence hampered PMN chemotactic transmigration. While its role 
in secondary granule mobilization is evident, Ral has no control of the mobilization of primary 
and tertiary granules, and both damnacanthal and Ral23V only had effect on the degranulation of 
secondary granules.  
 
The mechanism by which Ral regulates secondary granule storage and release is unclear. By 
subcellular fractionation, I found that Ral is associated with the plasma membrane under resting 
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conditions, while chemoattractant stimulation triggers a translocation of Ral to secondary gra-
nules. Presumably, chemoattractant-induced cell surface endocytosis plays an important role in 
Ral intracellular translocation, and thus PMN degranulation. Since PMN chemoattractant recep-
tors are G protein-coupled, and clathrin-coated pits are generally employed to internalize these 
receptors after ligand binding, one possible hypothesis would be that Ral is in complex with the 
chemoattractant receptor and assembled into the clathrin pits after chemoattractant stimulation. 
However, testing this hypothesis using two inhibitors, dynasore and an AP-2 binding Eps15 pep-
tide, both specific blockers of clathrin-dependent endocytosis, failed to inhibit Ral translocation 
to the pool of secondary granules. Interestingly, several other inhibitors that generally inhibit en-
docytosis, vesicle transportation and/or cytoskeleton structures blocked Ral intracellular translo-
cation in the experiments.  
 
In different cells, Ral has also been implicated in other types of vesicle transportation, including 
both endocytosis and exocytosis [117-121]. However, the detailed mechanism regulating Ral ac-
tivity is not clearly understood.  
 
In platelets, it was found that Ral is inactive under resting conditions but becomes activated after 
stimulation [163]. Contrary to our observation in this study, scientists in another study showed 
that Ral is inactive in resting PMN [215], a variation that was likely caused by different methods 
of cell preparation. In other studies, a guanine nucleotide dissociation stimulator, RalGDS, has 
been suggested to be important in regulating Ral [164, 224], and such regulation involves Ras. In 
particular, RalGDS was shown to directly bind to Ras, suggesting that Ral acts as a downstream 
effector in the Ras network [167, 225]. However, evidence obtained from my studies fall short of 
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supporting an important role of RalGDS in Ral-mediated degranulation in PMN. First, I found 
that the expression of RalGDS in PMN is trivial compared to many other cell types (Figure 4-1), 
and is also in no match for the abundance of Ral (Figure 4-1A).  Second, subcellular fractiona-
tions detected no co-localization of RalGDS and Ral in PMN under either resting or fMLF-
stimulated conditions. Contrary to Ral, which is translocated between plasma membrane and 
granules, RalGDS is consistently localized in the cytosolic fractions (Figure 4-1B). Studies of 
other cells have shown that RalGDS directly binds to Ras, suggesting that Ral acts as a down-
stream effector in the Ras network [201, 225]. However, I found that, in PMN, Ral has a com-
pletely different activity profile from that of Ras (Figure 3-6), suggesting a dissociation of Ral 
from the Ras pathway and a dispensable role for RalGDS in this regard.  
 
While the mechanism of activation of Ral is vital, especially during PMN maturation, in order to 
restrain produced granules in PMN, my results suggest the later mechanism that deactivates Ral 
is also undoubtedly crucial for converting naive PMN into potent, functional inflammatory leu-
kocytes. This mechanism, which is evidently important for PMN degranulation, remains un-
known. Specific molecules that promote Ral deactivation, such as GTPase activating proteins 
(GAPs), are hardly detected in any cell types including PMN. 
 
Previous studies have indicated a role of intracellular calcium in secondary granule release, the 
mechanism of how calcium functions is unclear. During chemoattractant (e.g. fMLF or IL-8) 
stimulation, the intracellular calcium concentration in neutrophils is generally increased to the 
peak ~10sec post-stimulation, followed by a quick decrease to the basal level (in the next ~1min) 
regardless of the continuous presence of the chemoattractant (Figure 4-2A). However, in the 
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same experimental setting, the robust release of secondary granules is observed approximately 
starting at ~1min and continuously to a much later time point (>30min) (Figure 4-2B). Thus, the 
time-course discrepancies of transient calcium increase in neutrophils versus the elongated re-
lease of secondary granule release after chemoattractant stimulation suggest that calcium likely 
serves as an important secondary messenger or a modulator, which activates downstream signal-
ing molecules directly involved in the control of secondary granule release. Since inhibition of 
Ral by damnacanthal triggers neutrophil degranulation in the buffer without calcium (in HBSS (-
)) (Table 1 & Figure. 3-1), I thus do not consider that damnacanthal-mediated downstream events 
(deactivation of Ral and secondary granule release) involve calcium or calcium signaling. How-
ever, my results did not exclude the possibility that calcium may regulate a step upstream of Ral 
deactivation. Indeed, Ral structurally contains a calmodulin binding site. Detailed studies of Ral 
activity at the very early phase of fMLF stimulation (within 1min) also sometimes showed a 
slight increase (10-20%) of Ral activity at 10-30sec (Figure 4-3A), a time-course correlating with 
the increase of intracellular calcium concentration. However, in vitro binding assays using the 
purified recombinant Ral and RalBP1 (one of the effectors of Ral) failed to demonstrate a direct 
involvement of calcium in Ral binding to this effector (Figure 4-3B).  
 
Surprisingly, during my work, I found that Mg
2+
 inhibited Ral activity in PMN, as demonstrated 
by a pull-down assay (Figure 4-4). Ral activity was strikingly increased in the presence of 2 mM 
EDTA, while EDTA did not change Ral activity in resting platelets (Figure 4-4A and Figure 3-
7B).  Since EDTA is a chelator for both Ca
2+
 and Mg
2+
, both cations are likely to be involved in 
regulating Ral activity. In order to dissect further which cation was the possible upstream inhibi-
tor of Ral, I first stimulated PMN with fMLF in HBSS (-) buffer without Ca
2+
 and assayed Ral 
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activity by pull-down. As shown in Figure 4-4B, stimulation of PMN in HBSS (-) failed to inhi-
bit Ral activity compared with stimulation of cells in HBSS (+). In addition, stimulation of PMN 
in the buffer supplemented with 5mM EGAT, a specific chelator for Ca
2+
, did not have any ef-
fect on Ral activity change. These results agree with other results (Figure 4-3B) and suggest that 
Ca
2+
 is not a regulator of Ral activity. Mg
2+
, however, inhibited Ral activity, which is shown in 
Figure 4-4C. Lysis of PMN in the presence of 30 mM Mg
2+
 abolished Ral activity. All of these 
results illustrate that Mg
2+
 is the potential upstream inhibitor of Ral in PMN.  
 
Treatment of PMN with damnacanthal in the absence of chemoattractant stimulation results in 
secondary granule release. However, the detailed mechanisms underlying damnacanthal-
mediated secondary granule release from PMN are unclear.  
 
It is obvious that the effect of damnacanthal on PMN is different from that of CB. As shown in 
Figure 3-1, treatment of PMN with fMLF+CB triggered robust PMN degranulation of all the 
granules including primary, secondary and tertiary granules. Treatment of PMN with damnacan-
thal, with or without fMLF, affected only the release of secondary granules. In experiments, I 
observed that pre-treatment of PMN with low dose damnacanthal (< 10 µM) followed by fMLF 
stimulation resulted in further degranulation in addition to the effect of damnacanthal alone (Fig-
ure 4-5). However, this manner of “synergenic” effect on secondary granule release was not ob-
served with pre-treatment of PMN with higher doses of damnacanthal (>10 µM), which alone 
triggered a near complete degranulation or complete degranulation without fMLF stimulation 
(Figure 3-1). Pretreatment of PMN with damnacanthal had no effect on fMLF-induced tertiary 
granule release (Figure 4-5). I further questioned whether receptor-mediated endocytosis in-
111 
volves in damnacanthal-mediated PMN secondary granule release. As shown in Figure 4-6 and 
Figure 4-7, treatment of PMN with only the endocytosis inhibitors had no effect on Ral distribu-
tion. In addition, pretreatment with endocytosis inhibitors appeared to have no effect, or only 
partial effect on damnacanthal-induced secondary granule release and Ral translocation from the 
plasma membranes to the granules.  These results, together with our other data (Figure 3-24), 
suggest that Ral deactivation might not be downstream of endocytosis or along the process of 
endocytic pathway. 
 
Taking everything into consideration, our results demonstrate that it is important to elucidate Ral 
activation and its importance in PMN; however, the mechanism that deactivates Ral is crucial for 
PMN degranulation, thus converting to functional inflammatory leukocytes. Ral deactivation 
correlates with clathrin-mediated endocytosis. Further studies of the signaling pathways and the 
precise protein interactions involved in clathrin-dependent Ral translocation would provide clues 
to resolve Ral conformational changes. In addition to Ral, other small GTPases, such as Ras fam-
ily members Ras and Rap, and Rho family members Rho, Rac and Cdc42 are also expressed in 
PMN [226-227] and some of these are found to be associated with granules [124, 131, 228]. 
Thus, detailed investigation of these small GTPases in PMN, and correlation of their activity 
changes with PMN activation and degranulation will shed new light on the understanding of 
PMN inflammatory functions. Given the critical role of PMN in innate immunity and inflamma-
tion, our findings illustrate a novel mechanism that modulates the PMN inflammatory response, 
which may provide a potential therapeutic target for treating various inflammatory conditions.  
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Figure 4-1. A) Expression of RalGDS in different cell types. Western blots were performed to 
detect RalGDS in the cytosol fraction of PMN (lane 1, same as Fig.5A) and total lysates of vari-
ous cell types using an anti-RalGDS antibody (Millipore). As shown, only slight amount of 
RalGDS was detected in PMN cytosol, total PMN lysates or PMN-like, DMSO-induced HL-60 
cell lysates. The same nitrocellulose membrane was re-blotted by anti-Ral antibody. The protein 
loading of each lane was normalized by detecting actin in the lysates.  B) RalGDS localization in 
PMN. After subcellular fractionation, Western blots were performed to detect RalGDS and Ral 
in the cytosolic and membrane fractions. As shown in the figure, RalGDS was exclusively loca-
lized in the cytosolic fractions in both unstimulated and fMLF-stimulated PMN and had no co-
localization with Ral which was associated with the plasma membrane and/or secondary gra-
nules.   
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Figure  4-2.  A study of chemoattractant stimulation-induced increase of intracellular calcium, 
secondary granule release and Ral activity changes in PMN.   A) Chemoattractant stimulation 
induces an increase of intracellular calcium in PMN. Freshly isolated PMN (1x10
6
) were loaded 
with the calcium indicator Indo-1 (Invitrogen) followed by washing. Labeled PMN in 1ml HBSS 
were transferred into a cuvette (Starstedt) and placed into the spectrofluorimeter that had been 
thermostated to 37°C. After equilibration, PMN were stimulated with 1µM fMLF (at 50sec posi-
tion) and cytoplasmic [Ca
2+
] changes were immediately recorded with fluorescence emission at 
505nm and double excitation wavelengths of 340 nm and 380nm using an intracellular cation 
software (Hitachi).  The concentrations of intracellular [Ca
2+
] were calculated using the Gryn-
ciewitz equation (R-Rmin) / (Rmax-R) * Kd (Kd is 2.54 x 10
-7
 M in this experiment). Rmax and 
Rmin were measured by adding digitonin (10µM) and then EGTA (20mM) to Indo-1-loaded 
PMN. Autofluorescence was corrected by stimulation of non-Indo-1-loaded PMN.  The method 
of detecting intracellular calcium in PMN was also described previously [192]. B)  A parallel 
experiment detecting secondary granule release. PMN (2x10
6
) were resuspended in 0.1ml HBSS 
and equilibrated to 37°C. Following stimulation with 1µM fMLF for different time periods, the 
cell-free supernatants were collected after centrifugation and the released lactoferrin was assayed 
by ELISA using an anti-lactoferrin antibody.   
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Figure 4-3. A study of chemoattractant stimulation-induced increase of intracellular calcium, 
secondary granule release and Ral activity changes in PMN.   A) Ral activity changes in PMN 
after fMLF stimulation. In this experiment, PMN (1x10
7
) were stimulated with 1µM fMLF at 
37°C in HBSS for different time periods. After cell lysis, active Ral in PMN was recovered by 
RalBP1 pull-down followed by Western blot using an anti-Ral antibody. As can be seen in the 
figure, Ral activity was slightly increased (10-30%) immediately after fMLF stimulation (at ~10-
30 second). B) Calcium concentrations have no effect on the direct binding of RalA to RalBP1. 
In these experiments recombinant GST-RalBP1 and Tat-tagged wild-type and mutant RalA were 
produced by expression in E.coli followed by protein purification. Pull-down assays were per-
formed by incubation (30min, 4°C) of GST-RalBP1(1µg) with Tat-tagged Ral (0.2µg each) in 
HBSS containing 5% non-fat dry milk, 2% BSA, 0.01% Tween 20 and different concentrations 
of CaCl2. Glutathione-conjugated Sepharose (20µl) were also added. After washing, proteins 
pulled down by the Sepharose were analyzed by Western blot using an anti-Ral antibody. As can 
be seen in the figure, only the constitutively active Ral (Ral23V) was directly pulled down by 
RalBP1. Increasing calcium concentrations had no effect on the direct binding of Ral to RalBP1.    
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Figure 4-4. Mg
2+
 inhibits Ral activity in PMN. A) Ral activity in freshly isolated PMN was in-
creased in the presence of EDTA. PMN were lysed in the presence or absence of 2mM EDTA, 
and active Ral was pulled down using RalBP1. In addition, resting platelets were lysed in the 
presence of 2mM EDTA, and active Ral was pulled down by RalBP1. B) Detecting activity 
changes of Ral in PMN. PMN were stimulated with fMLF (1µM) in HBSS (-), HBSS (+), or 
HBSS (+) supplemented with 5mM EGTA. After time-course stimulation, PMN were lysed, and 
active Ral was pulled down. Cell lysates before pull-down were used to detect total Ral as well 
as actin using antibodies against Ral and β actin. C) Detecting activity changes of Ral in PMN. 
PMN were lysed in the presence of 5mM EDTA or 30nM Mg
2+
, and active Ral was detected by 
pull down assay.  
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Figure 4-5.  Effects of damnacanthal alone or in a combination with fMLF on PMN granule re-
lease. In these experiments, aliquots of freshly isolated PMN (1x10
7
) were treated with vehicle 
(0.1% DMSO, 15min, 25°C), damnacanthal (3.6µM and 9µM, 15min, 25°C), fMLF (1µM, 
15min, 37°C), or damnacanthal (3.6µM, 15min, 25°C) followed by fMLF (1µM, 15min, 37°C). 
An aliquot of PMN resuspended in HBSS(-) and kept at 25°C (15min) was also used as a control 
condition. After incubation, cell-free supernatants were collected after centrifugation and assayed 
for granule release. Left: assay of PMN secondary granule release by detecting lactoferrin in the 
supernatants. Right: Assay of PMN secondary granule release by zymogram detecting liberated 
gelatinase in the supernatants.  
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Figure 4-6. Subcellular fractionations studying the effects of damnacanthal and endocytosis in-
hibitors on Ral distribution in PMN. Damnacanthal triggers Ral redistribution from the plasma 
membranes into secondary granules. Freshly isolated PMN (1x10
8
/per condition) were treated 
with vehicle (0.1%DMSO) or damnacanthal (9µM) for 15min (25°C) before lysis and subjected 
to sucrose density gradients to separate subcellular organelles. After fractionation, the localiza-
tions of plasma membranes and intracellular granules in respective fractions were determined by 
their specific marker proteins (upper panels).  The lower panels show the Western blot results 
detecting Ral, SIRPα and JAM-A (junction adhesion molecule A) in the fractions. In PMN, 
SIRPα is mainly stored in secondary granules in the absence of stimulation, while JAM-A is 
consistently associated with the plasma membrane (unpublished data).  As can be seen, a portion 
of Ral was redistributed from the plasma membranes into secondary granules after damnacanthal 
treatment. Given that damnacanthal induces secondary granule release, it was predictable to ob-
serve that a portion of SIRPα was translocated to the plasma membranes. The indifferent JAM-A 
localization demonstrated that plasma membrane integrity was not jeopardized by damnacanthal. 
 
1-5 6 7 8 9 10 11 12 13 14 15 16 17 18
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
Plasma membrane ( Alkaline phosphatase)
Secondary granules ( Lactoferrin)
Primary granules (MPO)
R
e
c
o
v
e
r
e
d
 a
c
ti
v
it
y
 (
 O
D
 4
0
5
)
1-5 6 7 8 9 10 11 12 13 14 15 16 17 18
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Plasma membrane ( Alkaline phosphatase)
Secondary granules ( Lactoferrin)
Primary granules ( MPO)
R
e
c
o
v
e
r
e
d
 a
c
ti
v
it
y
 (
 O
D
 4
0
5
)
Damnacanthal (-fMLF)
Fraction number (#) Fraction number (#)
SIRPα
Ral 
JAM-A
Vehicle ctl (-fMLF)
#  1  6  7  8  9  10 11 12 13 14 15 16  17  18   #  1   6  7   8  9  10 11  12 13 14 15 16 17  18   Fraction number
118 
 
 
 
 
Figure 4-7. Subcellular fractionations studying the effects of damnacanthal and endocytosis in-
hibitors on Ral distribution in PMN. Inhibitors acting on clathrin-mediated endocytosis had no 
effect on damnacanthal-triggered Ral redistribution in PMN. In these experiments, PMN, pre-
treated with an individual endocytosis inhibitor (e.g. CPZ, 50µM) or a combination of several 
inhibitors (50µM CPZ + 20µM POA + 20mM succinic acid (pH5.5)) (10min, 25°C), were either 
subjected or not subjected to further treatment with damnacanthal (9µM) (15min, 25°C). After 
treatment, the cells were lysed followed by to sucrose density gradient centrifugation to separate 
subcellular organelles. After fractionation, Western blots were performed to detect Ral distribu-
tion in the fractions using an anti-Ral antibody. As shown in the figure, none of the endocytosis 
inhibitors markedly blocked damnacanthal-triggered Ral redistribution from the plasma mem-
branes to secondary granules. 
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CHAPTER V: 
APPENDICES (Data from other publications) 
I. PUBLICATION: ZEN K, CHEN CX, CHEN YT, WILTON R, LIU Y.RECEPTOR FOR 
ADVANCED GLYCATION ENDPRODUCTS MEDIATES NEUTROPHIL MIGRATION 
ACROSS INTESTINAL EPITHELIUM.J IMMUNOL. 2007 FEB 15; 178(4):2483-90. 
 
 
Figure 5-1. RAGE was amplified from human intestinal epithelial cells by RT-PCR.  Results 
showed that two fragments were amplified. Sequencing results showed that the longer fragment 
was 1.2kb matching the full-length RAGE (GeneBank # AB036432) and the shorter fragment 
was 0.9kb matching a N-terminal truncated RAGE form (GeneBank # AB061669). 
 
3.0 Kb
2.0 Kb
1.5Kb
1.0 Kb
0.5 Kb
1.2kb
0.9kb
AB1669         --------------------------------------------------------------------------------------------------------------------------
AB6432         MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEA 60
AB1669          ----------------------------------------------------------------------------------MNRNGKETKSNYRVRVYQI 19
AB6432          WKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQI 120                                             
**************************
AB1669          PGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRH 79   
AB6432          PGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRH 180                                
*******************************************************************************
AB1669          PETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQL    139
AB6432          PETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQL    240                
****************************************************************************    
AB1669         VVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYS 199
AB6432         VVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYS 300                
*****************************************************************************  
AB1669         CVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGV    259
AB6432         CVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGV    360                
***************************************************************************        
AB1669         ILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP 303
AB6432         ILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP 404                
******************************************** 
120 
 
Figure 5-2. RAGE was detected from epithelial cell lines by western blot. RAGE was detected 
from human colonic epithelial cells lines including T84 and HT29. RAGE was also detected 
from epithelial cell A549.  
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Figure 5-3. RAGE was detected in intestinal epithelial cells by immunofluorescence staining.  
Confluent T84 intestinal epithelial monolayers were quickly permeabilized and fixed with me-
thanol (10min, 4°C) followed by blocking with 5% normal goat serum. RAGE was detected us-
ing anti-RAGE antibody followed by labeling with FITC-conjugated goat anti-mouse IgG 
(H+L). Imaging was analyzed by confocal microscope (Zeiss).  
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Figure 5-4.  Generation of GST-exRAGE fusion protein. RAGE was amplified from the plasmid 
pcDNA3-RAGE-GST using the primers RAGE ECORI 91-F (ATATGAATTCGCTCAAAA-
CATCACAGCCCGGATT) and RAGE-XhoI (ATATCTCGAGTGGTTCGAT-
GATGCTGATGCT) and cloned into the vector (pGEX-5X1) through ECORI and XhoI, respec-
tively. GST-exRAGE fusion protein (61KD) was produced in the same way described in 2.7.1. 
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Figure 5-5. RAGE antibody titer test by ELISA. 96-well microtiter plate wells were coated with 
RAGE-ex/GST fusion proteins (5μg/ml each) overnight at 4ºC.After blocking with 1% BSA 
(30min, 25ºC), the wells were incubated with serum (1:200; 1:500; 1:1000; 1:2000; 1:5000; 
1:100000) for 30min. After washing, fusion protein binding to the antibody (serum) was detected 
by peroxidase conjugated goat anti-mouse Fc antibody. 
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Figure 5-6. RAGE antibody titer test by western blot. The serum from the mouse RAGE-ex(RL) 
and RAGE-ex(R) recognized the RAGE-Fc fusion protein, including the nonreducing form (A) 
and reducing form. (B). Antibody also picked the band form the HT29, PMN and monocyte. Af-
ter immunization for 5 times, the serum was used for WB at 1:1000 dilution.   
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Figure 5-7. RAGE detection from human PMN. RAGE was detected from human PMN using 
RAGE-ex serum. 3 samples out of 12 samples were RAGE positive. 
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II. Guo YL, Bai R, Chen CX, Liu DQ, Liu Y, Zhang CY, Zen K. Role of junctional adhe-
sion molecule-like protein in mediating monocyte transendothelial migration. Arterioscler 
Thromb Vasc Biol. 2009 Jan;29(1):75-83  
 
 
Figure 5-8. Generation of GST-JAML fusion protein. JAML-ex (AJ515553) was amplified from 
the Leukocyte cDNA library with the primers JAML-151-BamH I (ATAT GGATCC TGAAT-
GACTTGAATGTTTCC) and JAML-898-Xho I  (ATAT CTCGAG CAACTGATTACCACC-
CAAGAC) and cloned into the vector (pGEX-5X1) through BamH I and Xho I, respectively. 
JAML-CT was amplified from the leukocyte cDNA library with the primers JAML-979-BamH I 
(ATATGGATCCTGGTGAAGAAGACCTGTGGAAAT) and JAML-1278-XhoI 
(ATATCTCGAGAAGGGACTCTCCATTCTTCT) and cloned into the vector (pGEX-5X1) 
through BamH I and Xho I, respectively. 
GST-JAML-ex and GST-JAML-CT fusion protein 
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Figure 5-9. JAML antibody titer test by ELISA and western blot. 96-well microtiter plate wells 
were coated with RAGE-ex/GST fusion proteins (5μg/ml each) overnight at 4ºC.After blocking 
with 1% BSA (30min, 25ºC), the wells were incubated with serum (1:200; 1:500; 1:1000; 
1:2000; 1:5000; 1:100000) for 30min. After washing, fusion protein binding to the antibody (se-
rum) was detected by peroxidase conjugated goat anti-mouse Fc antibody. JAML was detected 
from human PMN and monocytes using anti-JAML-ex serum and anti-JAML-CT serum at 
1:1000 dilution.  
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Figure 5-10. JAML was expressed on PMN and monocytes. Human whole leukocytes were sur-
face labeled using anti-JAML-ex serum and anti-JAML-CT serum (control), respectively. RAGE 
expression was detected from PMN (R1 group) and monocytes (R2 group), but no lymphocytes 
(R3 group).  
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III. PUBLICATION: Liu Y, Tong Q, Zhou Y, Lee HW, Yang JJ, Bühring HJ, Chen YT, Ha 
B, Chen CX, Yang Y, Zen K. Functional elements on SIRPalpha IgV domain mediate cell sur-
face binding to CD47. J Mol Biol. 2007 Jan 19;365(3):680-93 
 
 
Figure 5-11. Ala57, Gln67, and Val57 were key amino acid residues mediating binding interac-
tion of SIRPα to CD47. 
 
Generation of SIRPα -IgV DNA constructs  
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